General Medicine and Primary Care: Recent Episodes
ReachMD
This CME series provides primary care professionals with the knowledge and skill sets needed to effectively provide standard-of-care medicine within the constraints of a busy office setting. Faculty therapeutic area experts address how to overcome barriers preventing optimal patient outcomes by improving guideline adherence, and optimizing practice performance in areas where guidelines are needed.
Guest: Paul Hunter, MD
The Advisory Committee on Immunization Practices (ACIP) recently updated their recommendations for the 2024-2025 flu season. Here to give us a breakdown of the key updates so we can protect our patients from the flu is family medicine physician Dr. Paul Hunter.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Jill Foster, MD
Guest: John Russell, MD
According to recent studies, co-administering the flu, RSV, and COVID-19 vaccines is generally safe, which is why both the CDC and Advisory Committee on Immunization Practices support this approach. However, there are some important considerations to keep in mind when co-administering these three respiratory vaccines, which is why Dr. Mary Katherine Cheeley speaks with Drs. Jill Foster and John Russell about best practices for co-administration and improving vaccination rates. Dr. Foster is the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School, and Dr. Russell is a family medicine physician at Jefferson Health System in Abington, Pennsylvania.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John Russell, MD
According to the CDC, flu vaccine coverage for all adults is about 47 percent, and there’s been a continued decline among pregnant patients and children since 2020. These reduced vaccination rates can have serious consequences for our patients and the healthcare system as a whole, which is why it’s so important for primary care providers to embrace their role in reversing this trend. To help in this mission, Dr. Charles Turck speaks with family medicine physician Dr. John Russell about strategies for boosting flu vaccination rates in the primary care setting.
Host: Jennifer Caudle, DO
Guest: A. Mark Fendrick, MD
Approximately 40 percent of the eligible U.S. population are not up to date with their colorectal cancer (CRC) screenings, which inspired this study that was presented at Digestive Disease Week (DDW) 2024 to help eliminate the colonoscopy backlog with stool-based CRC screening options. To learn the details of this study and how we can incorporate the findings into practice, join Dr. Jennifer Caudle as she speaks with Dr. Mark Fendrick, Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Laila Woc-Colburn, MD, DTM&H, FACP, FIDSA
Since annual flu shots help alleviate the severe disease burden on patients and the healthcare system as a whole, it’s important to make flu vaccination a part of every patient visit. Fortunately, tools like appointment reminders, in-office discussions, and infographics can help us integrate this preventative measure into routine patient care and protect them from the flu. To learn more about these strategies, Dr. Charles Turck speaks with Dr. Laila Woc-Colburn, Associate Professor at the Emory University School of Medicine in Atlanta.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Darvin Scott Smith, MD
Vaccines play a crucial role in preventing the flu itself, but there are a lot of lesser-known benefits of flu vaccination as well, including its impact on reducing illness severity, hospitalization rates, and co-infections as well as its importance in managing chronic diseases and enhancing public health outcomes. Joining Dr. Charles Turck to examine the comprehensive advantages of flu vaccination is Dr. Darvin Scott Smith, who’s an infectious disease consultant at San Mateo Medical Center in California.
Host: Caroline Piatek, MD
Guest: Irina Murakhovskaya, MD
Warm autoimmune hemolytic anemia (wAIHA) is a rare condition characterized by the premature destruction of red blood cells mainly by pathogenic IgG optimally active at 37oC. Innovative targeted therapies to address wAIHA are emerging, and many are likely to greatly improve patient outcomes when they reach the clinic. Join Drs. Caroline Piatek and Irina Murakhovskaya as they discuss in detail current and emerging non-antibody and monoclonal antibody therapies for wAIHA and how each has the potential to dramatically improve the treatment landscape for wAIHA.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Leigh Anne Cantrell, MD, MSPH
The updated ASCCP guidelines now address the use of dual-stain technology for cervical cancer management. CINtec PLUS Cytology is a test for the co-expression of p16 and Ki67 and confirms the presence of a transforming HPV infection and defines patients with high-risk cervical disease. To learn more about these guidelines and how to apply them in practice, join Dr. Leigh Cantrell, Medical Physician and Fellow in the American College of Obstetrics and Gynecology.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 07/24
Host: Robert Walker, PharmD
Guest: Nic Garner, PharmD
Travel vaccines are becoming increasingly common as they play a key role in protecting travelers abroad, but they’re only effective if patients actually receive them. That’s why Dr. Robert Walker speaks with Dr. Nic Garner, who shares best practices for counseling patients on travel vaccines. Dr. Garner is the District Support Pharmacist Leader at CVS Pharmacy in Texas with more than 10 years of community pharmacy management experience.
Host: Jody Takemoto, PhD
Guest: Donald Y. Leung, MD, PhD
There’s currently no way of knowing who’s going to develop a food allergy and who isn’t, which means early treatment or even prevention can't begin. But that might all change based on a recent study, which found that skin biomarkers may be able to predict the development of food allergies in pediatric patients. Here with Dr. Jody Takemoto to talk about these findings and their potential implications on food allergy care and prevention is Dr. Donald Leung, Head of Division of Pediatric Allergy and Immunology at National Jewish Health in Denver, Colorado.
Guest: Ashley L. Sumrall, MD
If we want to ensure that we and our patients have healthcare when we’re older and it continues to be available, it’s important to take a stand and be a part of advocacy work. There are multiple ways to get involved, and it’s not as intimidating as someone might think, so to share some of these strategies and the impact it could have on the future of healthcare, join Dr. Ashely Sumrall, Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Tyler J Bradshaw, PhD
In recent years, doctors have become interested in how large language models and AI technologies could potentially improve radiology overall. Even though these technologies are still in the beginning stages of being used in medicine, eventually doctors hope to show what impact they could have on patients. To learn more about these new technologies and imaging agents, join Dr. Tyler Bradshaw, Associate Professor in the Department of Radiology at the University of Wisconsin-Madison, who presented this topic at the SNMMI 2024 Annual Meeting.
Guest: Andres J. Yarur, MD
Health maintenance emphasizes health promotion and disease prevention, which is very important for patients with inflammatory bowel disease (IBD) since they’re at an increased risk of several life-threatening conditions. Tune in to hear Dr. Andres Yarur discuss essential health maintenance strategies for patients with IBD. Dr. Yarur is an Associate Professor of Medicine at Cedars Sinai Medical Center in Los Angeles, California.
Guest: Ashley L. Sumrall, MD
Advocacy is rooted in patients telling their stories, and every patient can be an advocate to help and allow others to hear about their experience. This has also helped clinicians get the medicine they need for their patients. Dive in to hear how you can incorporate advocacy strategies into your practice with Dr. Ashley Sumrall, Neuro- and Medical Oncologist, Hematologist, and Associate Professor at Atrium Health in Charlotte, North Carolina at the Levine Cancer Institute.
Guest: Lori J. Wirth, MD
Head and neck cancers are the seventh most common cancers globally and are increasing in prevalence.1,2 To dive further into the intricacies of this early-stage cancer, join Dr. Lori Wirth, Medical Oncologist in the Head and Neck Oncology Program at Massachusetts General Hospital in Boston.
References:
- Gormley M, et al. Br Dent J. 2022;233(9):780-786.
- Barsouk A, et al. Med Sci (Basel). 2023;11(2):42.
©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
US-NONO-00581 05/2024
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Christina Madison, BS, PharmD, BCACP, AAHIVP
The World Health Organization and the Vaccines and Related Biologics Products Advisory Committee recently recommended transitioning from quadrivalent to trivalent flu vaccines that exclude the B/Yamagata lineage. Explore the epidemiological data that led to this decision and counseling strategies that can help patients understand this new recommendation with Dr. Charles Turck and Dr. Christina Madison, founder and CEO of the Public Health Pharmacist.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jill Foster, MD
For optimal protection, the best time for patients to receive a flu shot is between September and October, but some patients may be hesitant. In fact, flu vaccination rates have been declining since the onset of the COVID-19 pandemic according to the CDC. That’s why Dr. Charles Turck speaks with Dr. Jill Foster about how we can help ensure patients receive timely and annual flu vaccinations. Dr. Foster is the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School in Minneapolis.
Guest: Darvin Scott Smith, MD
For optimal protection, the most prevalent flu strains are assessed every year and included in the vaccine. Here to talk about this process and the recent decision to exclude the B/Yamagata lineage from flu vaccines is Dr. Darvin Scott Smith, Infectious Disease and Geographic Medicine Consultant at San Mateo Medical Center in California.
Host: Warner K. Huh, MD
Guest: Kimberly Levinson, MD, MPH
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Llobet, MD
Guest: Holly Llobet, MD
Drs. Paul and Holly Llobet have been traveling the world as locum tenens physicians for over four years now, and their career has taken them to places they never would’ve expected. Tune in to learn more about their adventures in places like Guam and India as well as how locum tenens has impacted both their careers and relationship as husband and wife.
Guest: Jason Busse, PhD
In light of the opioid epidemic, the use of cannabis for therapeutic purposes is becoming of interest. But since there are other alternatives that are often more effective and have better safety profiles, it’s important to understand the evidence and guideline recommendations around these two treatment options. Here to share key considerations for using opioids and cannabis to treat patients living with chronic pain is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.
Host: Marianna Fontana, MD
Guest: Ronald Witteles, MD
Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss this opportunity to gain valuable insights and elevate your understanding of ATTR-CM treatment strategies!
Guest: Ripal Patel, MD, MPH
Guest: Trevor Cabrera, MD
Guest: Nick Kusnezov, MD
Guest: Marye Lois McCroskey, MD
Tune in to hear four clinicians from the Locumstory Physician Advisory Board share their experiences working as locum tenens and providing care to patients all over the world. This expert panel features Drs. Ripal Patel, Nicholas Kusnezov, Trevor Cabrera, and Marye Lois McCroskey, who all answer the question: why locum tenens?
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Jay L. Koyner, MD
In this episode of KDIGO Conversations in Nephrology, Dr. Kathleen Liu is joined by Dr. Jay Koyner to discuss the emerging field of persistent acute kidney injury (AKI). They delve into the question: what exactly is persistent AKI, and how does it differ from severe AKI? Dr. Liu and Dr. Koyner explore the key factors clinicians should consider when evaluating a patient's risk of developing persistent AKI. They also highlight the latest developments in this area of nephrology research, leaving listeners with valuable insights into the diagnosis and management of persistent AKI.
Join us as we discuss:
- What is persistent AKI, and how is it distinguished from severe AKI?
- What clinical factors should be considered when assessing a patient's risk of persistent AKI?
- What are some of the new developments in the field of persistent AKI research?
- How can this knowledge be applied to improve patient care?
This episode is supported by an independent educational grant from Baxter.
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Professor Claudio Ronco
This episode dives into the recent advancements and best practices surrounding Extracorporeal Blood Purification within the complex scenario of multiorgan support. Join Drs. Kathleen Liu and Claudio Ronco as they engage in a thought-provoking discussion, exploring:
- Recent clinical trials suggesting minimal benefits of early CRRT in AKI for critically ill patients. The conversation delves into whether these findings translate to patients experiencing multiorgan failure, exploring the potential differentiating factors.
- The potential of CRRT to extend beyond renal support. The discussion explores how CRRT might offer support to other vital organs in the setting of multiorgan system failure.
- The role of current CRRT technology in eliminating inflammatory mediators. Dr. Ronco sheds light on the capabilities of current technology and its potential impact on the inflammatory response.
Join Dr. Liu and Dr. Ronco for an insightful exploration of extracorporeal blood purification’s evolving role in optimizing care for critically ill patients.
This episode is supported by an independent educational grant from Baxter.
Host: Kathleen Liu MD, PhD, FASN, BRCU
Guest: Kianoush B. Kashani MD, MS, MSc, FASN, FCCP
In this episode, Dr. Kathleen Liu welcomes Dr. Kianoush Kashani to discuss the rising importance of personalized care in Acute Kidney Injury (AKI) treatment. They delve into the world of digital health, exploring how digital decision support tools can empower clinicians and improve patient outcomes.
This episode will address:
- Digital Health: Dr. Kashani breaks down the concept of digital health and its applications in the context of AKI management.
- The Power of Digital Tools: Discover how digital decision support systems can aid clinicians in early detection, risk stratification, and personalized treatment plans for AKI patients.
- Personalized Care for AKI: Dr. Liu and Dr. Kashani explore why a one-size-fits-all approach doesn't work for AKI, and how digital tools can pave the way for individualized care.
- Optimizing KRT Outcomes: Learn how digital health can improve decision-making around KRT, leading to better patient outcomes.
Tune in for this informative discussion on leveraging the power of digital health to personalize AKI care.
This episode is supported by an independent educational grant from Baxter.
Host: Marianna Fontana, MD
The HELIOS trials, a groundbreaking phase 3 program, are investigating the potential of vutrisiran, an RNA interference (RNAi) therapy, to combat both hereditary and wild-type ATTR amyloidosis. Building on a successful phase 1 study demonstrating vutrisiran's safety and effectiveness in reducing serum TTR, HELIOS is paving the way for a new era in ATTR treatment.
Join Dr. Marianna Fontana as she highlights the cardiac exploratory analysis of HELIOS-A and the design of HELIOS-B.
Guest: Dena Goffman, MD
Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a new, ingenious hemorrhage tool and embraced simulations to train and improve the skills of healthcare professionals throughout the labor and delivery process. Join health and science journalist Catherine Price as she speaks with Dr. Dena Goffman, Vice Chair for Quality and Patient Safety and the Associate Chief and Quality Officer for Obstetrics for NewYork-Presbyterian, about how her work has helped establish goals and quality standards for safer labor and delivery.
© 2024 NewYork-Presbyterian
Host: Tauseef Ali, MD, FACG, AGAF
Host: Sabina Ali, MD
Host: Neil Nandi, MD, FACP
Host: Tina Aswani-Omprakash, MPH
A South Asian pediatric gastroenterologist discusses the epidemiology of IBD, distinct phenotypes, the latest clinical data from the mainland and diaspora, patient burden, and the importance of providing culturally competent care.
Host: Kevin Trice, MD
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Michael E. Yurcheshen, MD, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Seema Khosla, MD, FCCP, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Alcibiades J. Rodriguez, MD, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Anne Marie Morse, DO, FAASM
One billion people worldwide are estimated to have Obstructive Sleep Apnea (OSA). There is strong data linking OSA with morbidity and mortality. Many of your patients are likely experiencing symptoms of OSA, and you can make a difference. OSA screening is a missed opportunity in the primary care setting and can be easily implemented to ensure that the necessary steps are taken to get the patients into treatment and to improve patient outcomes. The purpose of this educational program is to help primary care providers learn how to screen for OSA, implement an OSA screening process, and develop a road map for cross-specialty collaborative relationships between sleep specialists and primary care clinicians.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Michael A. Levine, MD, FAAP, MACE, FACP
Host: B. Michelle Schweiger, DO, MPH
Autosomal Dominant Hypocalcemia Type 1 (ADH1) is caused by gain-of-function variants of the CASR gene encoding the calcium-sensing receptor (CaSR), resulting in hypocalcemia, inappropriately low parathyroid hormone levels, and hypercalciuria. While this has been defined and reported upon, the role CaSR plays in maintaining calcium homeostasis and the potential role it might have in different patient types (from pediatric to adult population) is not well understood clinically. Furthermore, with newly published data imminent surrounding encaleret, providers must be knowledgeable about the implications associated with the new literature and the implications it has towards the practice of hypoparathyroidism.
Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA
A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.
Guest: Carl Danzig, MD
Guest: Arshad M. Khanani, MD, MA
Dr. Carl Danzig, Director of Vitreoretinal Services and Retina Clinical Research of Rand Eye Institute in Deerfield Beach, Florida, and Dr. Arshad Khanani, Clinical Associate Professor at the University of Nevada in Reno, Nevada, will present key data about anti-VEGF therapies for retinal vein occlusion (RVO). Join the discussion on developing treatment protocols that use current therapies most effectively to improve outcomes and individualized treatment protocols for patients who are nonresponsive to first-line therapies and who require chronic treatment for macular edema.
Host: Scott Kahan, MD, MPH
Guest: Ken Fujioka, MD
Guest: Carol Wysham, MD
Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management.
Host: John K. Botson, MD, RPh
Guest: Xu He, MD
Many patients with gout don’t achieve their target urate levels with conventional urate-lowering therapies. Join renowned experts Drs. Xu He and John Botson as they dissect the potential benefits of urate reduction, discuss management options for patients with uncontrolled gout, and underscore the critical significance of timely referrals from primary care to specialty care in optimizing outcomes for patients with uncontrolled gout.
Host: Annie Levesque, MD, MSc
Guest: Ethan A. Cowan, MD
Alcohol use disorder, or AUD, is a rising health crisis that often goes undiagnosed. And many patients that are diagnosed with AUD do not receive appropriate pharmacologic intervention or even a referral. Join Drs. Levesque and Cowan in this case-based educational program as they provide critical diagnostic and treatment strategies for use in the office/clinic setting and the Emergency Department.
Host: Lee Shulman MD, FACOG, FACMG
Guest: Kristina Deligiannidis, MD
The recent development and approval of two neuroactive steroids is likely to change the treatment paradigm for moderate to severe postpartum depression (PPD). These agents have a quick onset and function as GABAA positive allosteric modulators. Join Drs. Shulman and Deligiannidis as they address the burdens and impacts of PPD on mothers, babies, and partners, and deep dive into the pathophysiologic role and clinical findings associated with the use of neuroactive steroids in the management of PPD.
Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?
Host: Manesh R. Patel, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: M. Cecilia Bahit, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Manesh R. Patel, MD
Host: M. Cecilia Bahit, MD
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: Christopher B. Granger, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Guest: Cara Dolin, MD
Guest: Jennifer Simpson
Guest: Diana Girnita, MD ,PhD
Explore this video roundtable featuring an interdisciplinary panel of experts discussing a woman’s journey with mycophenolate therapy and strategies to approach risk mitigation. Learn more about how to provide critical education on the risks of mycophenolate, the importance of effective contraception, and navigating family planning.
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Guest: Julie A. Barta, MD, ATSF
Host: Peter J. Mazzone, MD, MPH, FCCP
Early detection of lung cancer is difficult, with many cases going undetected until it is too late. New methods using minimally invasive liquids biopsy and molecular biomarkers are in development to improve early detection of lung cancer. Join Dr. Peter Mazzone and Dr. Julie Barta as they discuss the latest data around two new blood-based assays with promising results for detecting lung cancer in high-risk individuals and the potential for improving patient survival.
Host: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.
Host: Richard Johnson, MD
Guest: Brittany Weber, MD, PhD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: John K. Botson, MD, RPh
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: John K. Botson, MD, RPh
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Richard Johnson, MD
Guest: Abdul Abdellatif, MD, FASN
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Abdul Abdellatif, MD, FASN
Guest: Richard Johnson, MD
Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Marco Metra, MD
Guest: Gianluigi Savarese, MD
Clinical trials provide evidence to support guideline recommendations. What’s changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.
Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Guest: Maria Luiza Caramori, MD, PhD, MSc
Guest: Ana Maria Cebrián-Cuenca, MD, PhD
Guest: Pam R. Taub, MD, FACC, FASPC
Optimal treatment with guideline-directed therapies, including RAS inhibitors, SGLT2 inhibitors, and nonsteroidal MRAs, is paramount in preventing progressive renal dysfunction and cardiorenal events in patients with chronic kidney disease and type 2 diabetes. As the patient becomes more complex, a multidisciplinary approach is often necessary to improve their outcomes. Listen in as our panel of experts offers strategies to improve collaboration and patient care.
Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Patrick Rossignol, MD, PhD
Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Guest: Natalia Castillo Almeida, MD
感染流感会增加住院和罹患严重疾病的风险，尤其对高风险患者而言。幸运的是，接种流感疫苗可以帮助个人有效应对此类情况。在本节目中，内布拉斯加州大学医学院传染病系助理教授 Natalia Castillo Almeida 医生分享了关于住院率的关键数据和流感疫苗的接种建议。
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Alan H.B. Wu, PhD
Liver disease patients are at an increased risk of major adverse cardiovascular events (MACE), which is why the doctor in today’s episode believes the multidisciplinary team plays an essential role in managing these patients. Tune in with Dr. Charles Turck as he speaks with Dr. Zobair Younossi, Chair of the Global NASH Council and Professor of Medicine at the Inova Fairfax Medical Campus in Falls Church, Virginia.
Host: Peter Lin MD, CCFP
Guest: Ikechi Okpechi
In this episode, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Ikechi Okpechi (University of Alberta, Canada) discuss the right time to refer patients with CKD to a nephrologist. This episode also addresses rapid CKD progression and the utility of risk prediction equations.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Sri Lekha Tummalapalli, MD, MBA, MAS
Join host, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Dr. Lekha Tummalapalli (Weill Cornell Medicine, United States) as they discuss the importance of early CKD detection. This episode explores risk factors, screening for CKD, and country-specific factors to take into account when screening for CKD.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Joel Topf, MD
Join host Dr. Peter Lin (Canadian Heart Research Centre, Canada) in conversation with Dr. Joel Topf (Oakland University, William Beaumont School of Medicine, USA) as they discuss how to combat CKD progression and the role of non-pharmacological vs pharmacological interventions. This episode will explore whether foundational therapies are underused and how to tailor the right treatment for the right patient at the right time.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Peter Lin MD, CCFP
Guest: Magdalena Madero, MD
In this episode, Dr. Peter Lin (Canadian Heart Research Centre, Canada) and Dr. Magdalena Madero (National Heart Institute Mexico City, Mexico) discuss best practices for CKD evaluation and measurement. This episode focuses on the importance of assessing GFR and albuminuria, identifying the causes of CKD, CKD progression, and when more accurate GFR measures (such as cystatin) should be conducted.
This episode is supported by an independent educational grant from AstraZeneca.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: John J. Russell, MD
Guest: Darvin Scott Smith, MD
Hospitals and health systems face several economic and logistical challenges due to low rates of flu vaccination. Fortunately, there are policies, programs, and initiatives that can be implemented in health system environments and at the community level to increase flu vaccination rates. Learn more with Drs. Darvin Scott Smith and John Russell. Dr. Smith is an Infectious Disease Consultant of Public Health Works, LLC in Northern California, and Dr. Russell is a family medicine physician at Jefferson Health System in Abington, Pennsylvania.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Vaccines are essential in reducing death and disability related to influenza, but unfortunately, not all patients have equal access to these life-saving resources. In fact, many barriers exist, like misinformation and lack of public awareness and education. That’s why Dr. Charles Turck speaks with Dr. Keith Ferdinand about ways we can break down barriers and improve vaccination rates among members of racial and ethnic minority communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph F. Goldberg, MD, MS
Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
August 2023 US.UNB.X.23.00071
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Darvin Scott Smith, MD
There are several benefits associated with using real-world evidence to assess vaccine effectiveness, especially in the context of flu vaccines. Find out why and what the real-world evidence says about the effectiveness of flu vaccines with Dr. Charles Turck and Dr. Darvin Scott Smith. Dr. Smith is an infectious disease consultant of Public Health Works, LLC in Northern California.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jill Foster, MD
The clinical and economic burden associated with the flu is particularly heavy for our youngest patients. Learn more about this burden and how influenza vaccines can help reduce it with Dr. Charles Turck and Dr. Jill Foster, Professor in the Department of Pediatrics and the Director of the Division of Pediatric Infectious Diseases at the University of Minnesota Medical School in Minneapolis.
Host: Joyce Riley
Guest: Lance Sloan, MD
Pneumococcal vaccination isn’t restricted to a specific season. Patients can get vaccinated with Prevnar 20 at any time. Clinicians can help their patients better understand the importance of pneumococcal vaccination. Join Joyce Riley as she gets expert insights from Dr. Lance Sloan, Endocrinologist, Nephrologist, and Metabolist in Lufkin, Texas.
Continuing medical education credits are not available for this program.
Guest: Candace T. Westgate, DO, MPH, FACOG
Guest: Ethan D. Schram, MD, FACP
Early detection of cancer is essential to reducing the significant burdens associated with it. When cancer is detected at earlier stages, treatments can be initiated sooner, resulting in improved outcomes, reduced morbidity and mortality, and better quality of life. While the implementation of current screening guidelines has resulted in an overall reduction in cancer deaths, only 25 percent of cancers are diagnosed using traditional screening modalities, leaving much room for improvement. Blood-based multi-cancer early detection, or MCED, tests that can screen from four to greater than 50 types of cancers have been developed to complement the population-based screening of asymptomatic individuals. At the spring 2023 American Association for Cancer Research, also known as AACR, American Society of Clinical Oncology, or ASCO, and National Comprehensive Cancer Network, orNCCN, annual conferences, a multitude of data was presented on MCEDs, including real-world data, clinical trial data, novel MCEDs in development, MCED accuracy, and the inherent health equity challenges that their implementation will face. This educational activity has two parts. Dr. Candace Westgate delivers an MCED Primer designed to build primary care clinicians’ knowledge about the science of MCEDs and how to implement their use in primary care practice, followed by chapterized discussions between …
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
We all face angry and disruptive patients from time to time, making it essential to know how to properly de-escalate and handle the situation. That’s why Dr. Peter Buch speaks with Dr. Douglas Drossman, co-author of an article that was published in the American Journal of Gastroenterology titled “De-escalate, Don’t Escalate: Essential Steps to Effectively Recognize and Manage the Patient Who Is Angry and Disruptive.”
Guest: James Galvin, MD, MPH, FANA
Guest: Jon Toledo, MD, PhD
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this program employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity focuses on the role of primary care physicians (PCPs) in the monitoring, recognition, and management of ARIA. This includes an overview of baseline needs surrounding Aβ-DMT, potential presentations of ARIA in primary care, courses of action that may be needed regarding its evaluation/treatment, and communication throughout care.
Note that the core activity is supplemented by an
Host: Ryan Maves, MD
Guest: Megan Conroy, MD, MA(Ed)
Respiratory syncytial virus (RSV) is most commonly recognized for the significant disease it causes in infants and young children. However, over time its prevalence in adults has increased. Tune in to learn more with Dr. Ryan Maves as he speaks with Dr. Megan Conroy, Assistant Professor of Medicine at the Ohio State University in Columbus.
This program is produced in partnership with the American College of CHEST Physicians and is supported by an educational grant from GSK.
Host: Ryan Maves, MD
Guest: Kelly Pennington, MD
It’s estimated that respiratory syncytial virus (RSV) is responsible for up to 30 percent of viral respiratory infections in the stem cell transplant population. So how can we help RSV patients achieve their best outcomes? Learn more with Dr. Ryan Maves as he speaks with Dr. Kelly Pennington, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota.
Guest: Natalia Castillo Almeida, MD
Influenza can increase the risk of hospitalization and disease severity, specifically for high-risk patients. Fortunately, the influenza vaccine can help combat this. Join Dr. Natalia Castillo Almeida, an Assistant Professor in the Division of Infectious Diseases at the University of Nebraska School of Medicine, as she shares key data on hospitalization rates and recommendations for vaccination.
Host: Piotr Ponikowski, MD, PhD, FESC, FHFA
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Patrick Rossignol, MD, PhD
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This activity is part of a series of six distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This activity finishes out the series by first providing an abbreviated outline of what has been addressed across activities 1-5 followed by a multidisciplinary discussion of questions and considerations that may impact the team-based execution of discussed strategies.
It’s estimated that 20 percent of the world’s population has elevated Lp(a) greater than 50 milligrams per deciliter. Lp(a) is an independent, genetic, and causal risk factor for atherosclerotic cardiovascular diseases. For more insights, tune into this episode sponsored by Novartis.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
Elevated lipoprotein(a), or Lp(a), is the most common inherited dyslipidemia that can drive the atherosclerotic process. So at what age does Lp(a) impact a patient’s life? To find out more, tune into this episode sponsored by Novartis.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
Guest: Santica Marcovina, PhD, ScD
Lipoprotein(a), or Lp(a), is a unique apoB family lipoprotein that contains apo(a), which is a peculiar carbohydrate-rich protein covalently bound to an apoB lipoprotein. So are elevated Lp(a) levels a risk factor for atherosclerotic cardiovascular disease? Dive into this episode, sponsored by Novartis, to find out.
Sponsored by Novartis Pharmaceuticals Corporation.
6/23 278623
Host: Charles P. Vega, MD
Obesity and overweight have reached epidemic status in the US. While safe and effective treatment options are available, it remains a challenge for clinicians to initiate conversations about weight with their patients. Learn how to open channels of communication with your patients by watching Dr. Charles Vega interact with a 42-year-old patient using shared decision-making.
Host: Neda Shamie, MD
Guest: Jay S. Pepose, MD, PhD
Jay S. Pepose, MD, PhD, sits down with Neda Shamie, MD, to talk about a phase 3 multicenter, randomized, placebo-controlled, double-masked clinical trial that evaluated the safety and efficacy of 0.75% phentolamine ophthalmic solution for the reversal of pharmacologically induced mydriasis. What were the findings of the MIRA-2 study?
Host: Neda Shamie, MD
Guest: Julie Schallhorn, MD
Julie Schallhorn, MD, joins Neda Shamie, MD, to discuss a review conducted by the AAO of the published literature on the safety and efficacy of presbyopia-correcting IOLs available in the United States. Learn more about the findings.
Host: Neda Shamie, MD
Guest: Jason Bacharach, MD
Jason Bacharach, MD, sits down with Neda Shamie, MD, to discuss a randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial that evaluated the IOP-lowering efficacy and safety of the bimatoprost implant (Durysta, Allergan) in patients with open-angle glaucoma or ocular hypertension. What were the results?
Host: Neda Shamie, MD
Guest: Marguerite McDonald, MD, FACS
Marguerite McDonald, MD, FACS, and Neda Shamie, MD, discuss a literature review and panel discussion that sought to develop a consensus statement on the classification of presbyopia by severity. What were the results?
Host: Neda Shamie, MD
Guest: Francis Mah, MD
Francis Mah, MD, joins Neda Shamie, MD, to discuss a post hoc analysis of data from a phase 3 evaluation of the safety of netarsudil 0.02% compared to timolol 0.5%. Learn the results.
Host: Neda Shamie, MD
Guest: Kendall Donaldson, MD
Kendall Donaldson, MD, sits down with Neda Shamie, MD, to discuss a retrospective chart review in which investigators evaluated the refractive outcomes of phacoemulsification in eyes with Fuchs endothelial corneal dystrophy. Did results differ between eyes that underwent laser cataract surgery and those that received conventional phacoemulsification?
Host: Neda Shamie, MD
Guest: Cynthia Matossian, MD
Cynthia Matossian, MD, joins Neda Shamie, MD, to discuss a national, noninterventional, cross-sectional, mixed methods survey that evaluated cataract surgery candidates’ knowledge and emotions as they related to cataract surgery and their behavioral intent to adhere to a doctor-recommended presurgical ocular surface prep routine. Learn more about commonly held assumptions.
Host: Neda Shamie, MD
Guest: Brandon D. Ayres, MD
Brandon D. Ayres, MD, joins Neda Shamie, MD, to discuss an FDA clinical trial that evaluated the safety and efficacy of a custom-manufactured artificial iris device (CustomFlex ArtificialIris, HumanOptics) for the treatment of congenital and acquired iris defects. Learn the results.
Host: Neda Shamie, MD
Guest: Inder Paul Singh, MD
Inder Paul Singh, MD, sits down with Neda Shamie, MD, to discuss a retrospective analysis that evaluated the Medicare claims–based 5-year economic and reintervention burden for patients with primary open-angle glaucoma after incisional glaucoma surgery in the United States. What do the findings suggest for clinical and surgical practice?
Host: Charles P. Vega, MD
Guest: Pradeep S. Prasad, MD, MBA
Vision loss due to diabetes is preventable, yet minority patients and patients of low socioeconomic status remain at a disproportionate risk of poor outcomes. Find out what Dr. Pradeep Prasad and Dr. Charles Vega are doing to curb the negative outcomes of diabetic eye disease in their patients at high risk for vision loss.
Host: Charles P. Vega, MD
Guest: Donna Ryan, MD
Addressing the health issues of your patients with obesity can present a challenge. How can you initiate the conversation and effectively emphasize the benefits of weight loss? Join Drs. Charles Vega and Donna Ryan as they review a case of obesity and use evidence-based medicine to develop a patient-centric treatment plan.
Host: Charles P. Vega, MD
Guest: Donna Ryan, MD
Obesity is a chronic, progressive disease which has often been overlooked by physicians, leaving a considerable proportion of people with obesity underdiagnosed and inappropriately managed. Join Drs. Charles Vega and Donna Ryan as they break down the pathophysiology of obesity and discuss currently available weight-loss medications.
Host: Charles P. Vega, MD
Guest: Sharon D. Solomon, MD
New treatments are available to manage diabetic macular edema (DME) that have the added benefit of reducing treatment burden. This can level the playing field and benefit patients who are less likely to access routine healthcare. Tune in to hear Dr. Sharon Solomon and Dr. Charles Vega discuss how the latest clinical data measure up by prolonging treatment intervals and how retina specialists are now better equipped to care for their most vulnerable patients with DME.
Host: Charles P. Vega, MD
Guest: Ruth Shoge, OD, MPH, FAAO
Racial and ethnic minorities are disproportionately affected by diabetic eye disease, which is one of the leading causes of vision loss in the United States. Hear how Dr. Ruth Shoge and Dr. Charles Vega are approaching patient care and find out what tools are available to you. Join us in overcoming barriers to vision care so that all patients can receive the treatment they need.
Host: Javed Butler, MD, MBA, MPH
Guest: John P. Boehmer, MD
Heart failure contributes to more than 3 million hospital admissions, resulting in a considerable economic burden. Despite significant developments to advance treatment, hospital readmission rates also remain high. Join Drs. Javed Butler and John Boehmer as they discuss fluid overload in patients with heart failure and explore recent clinical evidence in remote monitoring strategies to improve patient outcomes.
Host: Warner K. Huh, MD
Guest: Sarah E. Dilley, MD, MPH, FACOG
Effective triage tests are needed to lessen diagnostic uncertainty when assessing cervical cancer risk and selecting which patients will move on to colposcopy. An FDA-approved dual-staining cytology test is available that can help in decision-making for a wide range of patients. Join Drs. Warner Huh and Sarah Dilley as they address current 2019 ASCCP guidelines and anticipate potential updates to ASCCP’s guidance in 2023.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Scott D. Isaacs, MD FACP, FACE
Since type 2 diabetes is the number one risk factor for the progression to advanced liver fibrosis, monitoring diabetic patients is absolutely critical, especially considering the fact that the symptoms of disease progression can be nonexistent or very vague. Here with Dr. Mary Katherine Cheeley to break down the latest guidelines and strategies for monitoring liver health in patients with diabetes is endocrinologist Dr. Scott D. Isaacs.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Kwo, MD
Hepatitis B and C are both highly prevalent infections around the world. However, many individuals are not aware of their infection, which can lead to progressive liver damage and other health consequences. This is just one of the many unmet needs in the hepatitis care continuum, and joining Dr. Charles Turck to help uncover those unmet needs and discuss how the latest management strategies can help address them is Dr. Paul Kwo, Director of Hepatology at Stanford University.
Host: Mazen Noureddin, MD
Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.
Guest: Ripal Patel, MD, MPH
Guest: Trevor Cabrera, MD
Guest: Nick Kusnezov, MD
Guest: Marye Lois McCroskey, MD
Why locum tenens? To answer that question, four clinicians from the Locumstory Physician Advisory Board share their experiences providing care around the world and explore how working with locum tenens has impacted their careers.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Eric Klein, MD
Cancer remains the second-leading cause of death in the U.S., creating an urgent need to detect cancer at earlier stages when outcomes are better. With the emergence of novel multi-cancer screening technologies, the potential public health impact may be substantial. Given these advances, is it time to rethink the way clinical trials are designed to assess the effectiveness of these screening technologies? Joining Dr. Charles Turck to discuss how we can utilize surrogate endpoints to evaluate the efficacy of cancer screening modalities is Dr. Eric Klein, a distinguished scientist at GRAIL.
Host: Edwin A. Salsitz, MD, DFASAM
Guest: Ethan A. Cowan, MD
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Edwin A. Salsitz, MD, DFASAM
Guest: Annie Levesque, MD, MSc
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Guest: Edwin A. Salsitz, MD, DFASAM
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Guest: Edwin A. Salsitz, MD, DFASAM
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Annie Levesque, MD, MSc
Guest: Ethan A. Cowan, MD
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Guest: Ethan A. Cowan, MD
Guest: Edwin A. Salsitz, MD, DFASAM
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Annie Levesque, MD, MSc
Guest: Edwin A. Salsitz, MD, DFASAM
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Guest: Ethan A. Cowan, MD
Guest: Edwin A. Salsitz, MD, DFASAM
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Edwin A. Salsitz, MD, DFASAM
Guest: Ethan A. Cowan, MD
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Edwin A. Salsitz, MD, DFASAM
Guest: Annie Levesque, MD, MSc
The burden of Alcohol Use Disorder (AUD) is often overshadowed by the widespread opioid epidemic; however, AUD is one of the most prevalent and life-altering substance abuse disorders worldwide. Our multidisciplinary experts dive into various approaches to the treatment of AUD. Join Drs. Edwin Salsitz, Ethan Cowan, and Annie Levesque as they view AUD through their respective psychiatric, emergency department, and family medicine lenses.
Host: Jennifer Caudle, DO
Guest: Tamera A. Paczos, MD, FACOG, FACP
The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories.
COBAS and CINTEC are trademarks of Roche.
All other product names and trademarks are the property of their respective owners. 02/23
Host: Charles P. Vega, MD
Guest: George Grossberg, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to treat agitation in patients with Alzheimer’s dementia.
Host: Charles P. Vega, MD
Guest: Thomas W. Heinrich, MD
This Expert Exchange webcast is designed to improve clinicians’ ability to define, identify and assess agitation in Alzheimer’s dementia.
Host: Jennifer Caudle, DO
Guest: Stefanie Cribb, PharmD
Guest: Ryan Haumschild, PharmD
Guest: Jennifer Rubin
Guest: Ira Steinberg, MD
There’s been a lot of focus recently on biosimilars and their potential role in evolving the healthcare system. We're digging in deeper to understand what makes biosimilars so exciting. Joining Dr. Jennifer Caudle to discuss the biosimilar approval process and the important commitment supporting healthcare providers and patients in their adoption is a panel of experts: Dr. Stefanie Cribb, Dr. Ira Steinberg, and Ms. Jennifer Rubin from Coherus Biosciences and Dr. Ryan Haumschild from the Emory Healthcare and Winship Cancer Institute.
© 2022 Coherus BioSciences
C1122-COH-P829
Host: Darren Brenner, MD
Host: Brooks D. Cash, MD, AGAF, FACG, FASGE
Despite advances in the treatment of irritable bowel syndrome with constipation (IBS-C), many patients are still struggling. Our experts, Drs. Darren Brenner and Brooks Cash, discuss the complexity of this condition, its diagnosis, treatment recommendations, and clinical trial data. Tune in to be sure you’re using all of the tools at your disposal to improve your patients’ quality of life.
Host: Darren Brenner, MD
Host: Brooks D. Cash, MD, AGAF, FACG, FASGE
Despite advances in the treatment of irritable bowel syndrome with constipation (IBS-C), many patients are still struggling. Our experts, Drs. Darren Brenner and Brooks Cash, discuss the complexity of this condition, its diagnosis, treatment recommendations, and clinical trial data. Tune in to be sure you’re using all of the tools at your disposal to improve your patients’ quality of life.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Jamy Ard, MD
Guest: Michelle I. Cardel, PhD, MS, RD
Addressing obesity may be a key component of diabetes management, so integrating strategies to manage obesity may improve diabetes care. To better understand this, Dr. Jamy Ard and Dr. Michelle Cardel dive into the impact of evidence-based lifestyle interventions for people living with diabetes.
WW Logo and Weight Watchers are the trademarks of
WW International, Inc. and are used with permission.
Host: John J. Russell, MD
Guest: Stanton Miller, MD, MPH, FACS
Patients who live in an environment impacted by gun violence may face lifelong challenges. But addressing gun violence from a public health standpoint may help clinicians manage the biological, behavioral, and social aspects of this disease. Dr. John Russell is joined by Dr. Stan Miller from the Jefferson Center for Injury Research & Prevention to discuss how clinicians can reframe their approach.
Host: Matt Birnholz, MD
Guest: Jonathan Corren, MD
As recent research demonstrates the important role that TSLP plays in asthma inflammation, Dr Matt Birnholz is joined by Dr Jonathan Corren, an Associate Clinical Professor of Medicine and Pediatrics at David Geffen School of Medicine in Los Angeles. Together, they review how TSLP acts across the spectrum of asthma inflammation, the correlation of TSLP with clinical features of asthma, and more.
©2021 Amgen. All rights reserved. US-53813 Last Updated 6/21
Guest: Rajagopal Sekhar, MD
Clinicians are still working to understand the mechanisms behind age-related declines and what interventions might help promote healthy aging. Could supplementation with the nutritional compounds glycine and n-acetylcysteine (GlyNAC) play a role by improving intracellular antioxidant levels? Dr. Rajagopal Sekhar shares the latest clinical data on GlyNAC supplementation in older adults.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? Leading experts, Drs. Leigh Cantrell and Warner Huh, review the benefits of primary screening as they explore shifts in current guidelines. Find out how you can improve outcomes for patients, not only through appropriate primary HPV testing in lieu of cytology as the screening modality, but also by reinforcing how a “negative” HPV test actually sends a powerful “positive” message. As a bonus, you might just change a young patient’s life.
Host: John Buse, MD, PhD
Guest: Abbie E. Smith-Ryan, PhD, CSCS*D, FNSCA
There are immeasurable benefits to exercise, but the hard part for patients may be getting started. How can we help our patients make exercise a part of their lives? Dr. John Buse speaks with Dr. Abbie Smith-Ryan, a Professor of Exercise Physiology at the University of North Carolina – Chapel Hill, about the key benefits of exercise and how to encourage them for various patient populations.
Host: Vladimir Tesar, MD
Guest: Michael Walsh, MD
In this episode, host Dr. Vladimir Tesar (General University Hospital, Prague) and Dr. Micheal Walsh (McMaster University, Canada) explore the benefits of plasma exchange for patients with ANCA-associated vasculitis. This episode discusses how to identify patients who may benefit from plasma exchange and the role of plasma exchange in patients with double-positive ANCA and anti-GBM. The utility of rituximab in those also treated with plasma exchange will be addressed.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Vladimir Tesar, MD
Guest: David Jayne, MD
Host Dr. Vladimir Tesar (General University Hospital, Prague) and Dr. David Jayne (Addenbrooke's Hospital, United Kingdom) discuss the roles of various agents in the induction and maintenance treatment of ANCA- associated vasculitis. They will explore the use of rituximab and complement inhibition in treating ANCA-associated vasculitis. This episode will address the gaps in knowledge and ongoing research in the field of ANCA-associated vasculitis.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Vladimir Tesar, MD
Guest: Duvuru Geetha, MD
Join host, Dr. Vladimir Tesar (General University Hospital, Prague), in conversation with Dr. Duvuru Geetha (Johns Hopkins University School of Medicine, United States) as they discuss the main causes of delays in diagnosis of ANCA-associated vasculitis and the different ways to increase awareness of the disease. This episode will also discuss the role of kidney biopsy in the optimal management and monitoring of these patients.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Justin Cheeley, MD
Proper access to medication can present challenges for the doctor and patient but is necessary to achieve optimal patient outcomes. So how can they work together to eliminate this burden? To discuss this further, Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at Emory School of Medicine.
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Counseling your patients about their risk of shingles—and encouraging them to get vaccinated—can help better protect them. But how do we do that? To answer this question, Dr. Christopher Altman discusses the risk of shingles with Dr. Jennifer Caudle.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Shingles can impact many of our patients 50 years and older, which is why we need to talk to them about their risk. To take a look at counselling strategies, Dr. Jennifer Caudle is joined by Dr. Christopher Altman, Director of Immunization & Clinical Programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
How can we improve rates for shingles vaccination across all ethnicities? To find out how, Dr. Jennifer Caudle is joined by Dr. Christopher Altman to explore discrepancies in vaccination rates.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to discuss how to talk to vaccine-hesitant patients about shingles vaccination and share insights is Dr. Christopher Altman, Director of Immunization and Clinical programs.
Sponsored by GSK
Host: Jennifer Caudle, DO
Guest: Christopher D. Altman, PharmD
Joining Dr. Jennifer Caudle to explore how we should approach vaccine hesitancy and address concerns about cost and time constraints for shingles vaccination is Dr. Christopher Altman, Director of Immunization and Clinical Programs.
Sponsored by GSK
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Physicians and advanced practice registered nurses (APRNs) may practice differently but they can still get their patient to the same outcome. So where do the conflicts arise? Join Dr. Peter Buch as he walks us through this with Dr. Wendy Wright, nurse practitioner and founder of Wright & Associates Family Healthcare.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Frederic Rahbari-Oskoui, MD, MSc
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Jennifer Caudle, DO
Guest: William Lumry, MD
Hereditary angioedema (HAE) is a rare, genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 These swelling attacks can be both painful and debilitating, which is why prevention is so important.1 So what are the treatment options available that can help prevent HAE attacks? Joining Dr. Jennifer Caudle to discuss the importance of long-term prevention for HAE and the role of the treatment option TAKHZYRO (lanadelumab-flyo) is Dr. William Lumry, Clinical Professor of Internal Medicine at the University of Texas Southwestern Medical School.
IndicationTAKHZYRO® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in …
Guest: Dr. Timothy Craig
Hereditary angioedema (HAE) is a rare genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.2 The unpredictability of these attacks is a significant burden on patients.3 Fortunately, preventive treatments like TAKHZYRO® (lanadelumab-flyo) can help reduce the frequency and severity of HAE attacks.1 Here to share key information and data on this treatment option is Dr. Timothy Craig, Professor of Pulmonary, Allergy, and Critical Care Medicine at Pennsylvania State University.
IndicationTAKHZYRO® (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.
Important Safety InformationHypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.
Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.
Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.
No data are …
Host: Bradley Torphy, MD
Learn more about the efficacy and other clinical data for this preventive migraine treatment option. Dr. Brad Torphy highlights clinical data on this treatment option.
Host: Wade Cooper, DO
For patients with chronic or episodic migraine, what treatment options should we consider? To help answer that question, Dr. Wade Cooper discusses a treatment option for migraine.
Host: Jennifer Caudle, DO
Guest: Diane M. Harper, MD, MPH, MS
There are several testing methods available for cervical cancer screening, such as co-testing and primary HPV testing. So what are some of the most prominent benefits and limitations of these and other testing approaches? Joining Dr. Jennifer Caudle to break down the latest advancements in cervical cancer screening is Dr. Diane Harper, a Professor in the Departments of Family Medicine and Obstetrics and Gynecology at the University of Michigan.
Host: Fouad T. Chebib, MD
Guest: Pranav S. Garimella, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Fouad T. Chebib, MD
Guest: Pranav S. Garimella, MD
This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Paul Hunter, MD
It’s important to recognize that older adults are more susceptible to influenza infection—as well as increased severity of infection—than younger, healthier populations.1 Fortunately, there are vaccines available that can help prevent influenza in this aging population. But do the relative benefits and harms of higher-dose and adjuvanted vaccines, compared with one another and with other influenza vaccines, favor the use of any one or more of these vaccines over other age-appropriate options for people 65 and older?2 That's the exact question the CDC’s Advisory Committee on Immunization Practices (ACIP) sought to answer and what Dr. Charles Turck discusses with Dr. Paul Hunter, Associate Professor in the Department of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health.
References:
1. Centers for Disease Control and Prevention. Fly & People 65 Years and Older. Accessed August 16, 2022. https://www.cdc.gov/flu/highrisk/65over.htm.
2. National Center for Immunization & Respiratory Diseases. Advisory Committee on Influenza Practices. Influenza Vaccines for Older Adults: GRADE Summary. Accessed August 16, 2022.
USA-FLUD-22-0056 December 2022
Host: Sara W. Koblitz
Guest: Michael J. Thorpy, MD
While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we’re truly on the cusp of a new awakening in sleep medicine.
Host: Warner K. Huh, MD
Guest: Leigh Anne Cantrell, MD, MSPH
Guest: Mark H. Stoler, MD
Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Zobair M Younossi MD, MPH, FACP, FACG, AGAF, FAASLD
Guest: Scott D. Isaacs, MD FACP, FACE
Recently, the American Association of Clinical Endocrinology and the American Association for the Study of Liver Diseases released guideline updates on nonalcoholic steatohepatitis (NASH). How will these updates impact clinical practice? Drs. Zobair M.Younossi and Scott D. Isaacs join Dr. Charles Turck to share their insights on these updated guidelines.
Host: Ross M. Maltz, MD
Guest: Shail M. Govani, MD, MSc
Guest: Nana E. Bernasko, CRNP, WHNP-BC, DNP
Guest: Shubha Bhat, PharmD, MS, BCACP
As new therapies evolve, including biosimilars, it’s important for clinicians, patients, and caregivers to understand the similarities, differences, and potential risks and benefits of these therapies. Join our panel of experts to find out more about key concepts and best practices to educate your patients.
HPV testing plays an important role in cervical cancer screening, but not every patient whose HPV-positive will develop cervical cancer. One option that can help us identify which HPV-positive patients are truly at risk is CINtec PLUS Cytology, an immunohistochemistry test that simultaneously detects p16 and Ki67 biomarker proteins. Learn more about how this dual staining technique works in this video.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: David Mohr, PhD
In addition to potentially improving access to mental health care, digital tools have also been shown to improve symptoms in many types of mental illness1 and can serve as an adjunct to psychotherapy or pharmacotherapy. Despite this, these tools have not yet been widely adopted in the United States. So what are some strategies we can use to implement these tools and develop an improved framework? Joining Dr. Charles Turck to discuss mental health treatments and their application in clinical practice is Dr. David Mohr, a Professor in the Department of Preventive Medicine at Northwestern University Feinberg School of Medicine in Chicago.
Reference:
- Mohr DC, Azocar F, Bertagnolli A, et al. Banbury Forum Consensus Statement on the Path Forward for Digital Mental Health Treatment. Psychiatr Serv. 2021;72(6):677-683.
December 2022 US.UNB.X.22.00074
Guest: John Anderson, MD
HAE is a rare, autosomal dominant genetic disease that can cause recurrent, unpredictable, and potentially life-threatening attacks of swelling in the body.1 There are approximately 6,000 patients living with HAE in the U.S. alone,2 and it’s not uncommon for patients to go undiagnosed for years after they start experiencing symptoms.1 Since early diagnosis is vital to creating a management plan that meets each patient’s individual needs,2 Dr. John Anderson is here to share key information on how we can better diagnose HAE in our patients.
References:
- Banerji A. Hereditary Angioedema: Classification, Pathogenesis, and Diagnosis. Allergy Asthma Proc. 2011;32:403–407.
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
US-NON-7744v1.0 10/22
Host: Jenny S. Sauk, MD
It is estimated that only 20% to 30% of patients with Crohn’s disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.
Host: Sushila R. Dalal, MD
The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.
Host: Marlies Ostermann, MD
Guest: Rinaldo Bellomo, MBBS, MD, FRACP
In this episode, KDIGO Conversations in Nephrology host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), and Dr. Rinaldo Bellomo (University of Melbourne, Australia) will discuss the importance of hemodynamic stabilization in protecting kidney function for patients on kidney replacement therapy. This episode will also discuss the different strategies and therapies available for maintaining such stability. Urgent questions for future research will also be addressed.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Marlies Ostermann, MD
Guest: Javier Neyra, MD, MSCS
Join host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), in conversation with Dr. Javier Neyra (University of Alabama in Birmingham, United States) as they explore the role of kidney replacement therapy in managing fluid overload. They will discuss optimal monitoring and how best to remove fluid safely and effectively, including the evaluation of patients’ response to fluid removal prescription. This episode will also address the ongoing gaps in knowledge in the field.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Marlies Ostermann, MD
Guest: Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP
Join host, Dr. Marlies Ostermann (Guy's and St Thomas' Hospital, United Kingdom), in conversation with Dr. Sandra Kane-Gill (University of Pittsburgh School of Pharmacy, United States) as they discuss the importance of drug stewardship when treating critically ill patients. This episode will examine various terms such as drug-induced acute kidney injury, drug-associated acute kidney injury, and nephrotoxicity. Dr. Kane-Gill will also discuss how multiorgan support may influence drug dosing and aspects of nutrition and micronutrient supplementation for patients with AKI.
This episode is part of the KDIGO Conversations in Nephrology podcast series.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Natalia Castillo Almeida, MD
Patients in urban communities often face challenges when accessing influenza vaccines. But there are ways we can help address those geographic and socioeconomic barriers. Joining Dr. Charles Turck to share key strategies for improving influenza vaccination rates in urban communities is Dr. Natalia Castillo, Assistant Professor in the Division of Infectious Diseases at University of Nebraska Medical Center.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Piotr Kowalski, PhD
mRNA technology may have a potential role in several areas of gene editing. But are there any barriers to its application in clinical practice? Dr. Piotr Kowalski from the University College Cork explores mRNA technology in gene editing.
Host: David Schulman, MD, MPH, FCCP
Guest: William Lago, MD
Guest: Tejaswini Kulkarni, MD, MPH, FCCP
What are some of the barriers to early diagnosis for idiopathic pulmonary fibrosis (IPF)? Joining Dr. David Schulman to share their perspectives on the latest diagnostic challenges and provide strategies to combat them are Drs. Tejaswini Kulkarni and William Lago.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
Host: Kevin Cleveland, PharmD, ANP
Older adults face a variety of unique challenges that increase their risk of serious influenza infections. But fortunately, vaccinations can help address these challenges. Learn more with Dr. Kevin Cleveland, Associate Professor at the Idaho State University College of Pharmacy.
Host: Christina Madison, BS, PharmD, BCACP, AAHIVP
In the midst of a potential tridemic between COVID-19, RSV, and influenza, it’s now more critical than ever to raise awareness among patients about the importance of flu vaccines. Here to provide counseling strategies for educating patients about flu vaccines is Dr. Christina Madison, Associate Professor of Pharmacy Practice at Roseman University of Health Sciences.
Host: Jennifer Caudle, DO
Guest: Joseph Aloi, MD
The rate of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) continues to rise. What can we do to slow this progression of CKD? Dr. Joseph Aloi from the Wake Forest School of Medicine explores this growing epidemic and discusses how a new tool may aid in early risk assessment of early stage 1-3b CKD.
Host: Jennifer Caudle, DO
Guest: Carolyn Bridges, MD
We all know that influenza vaccinations can help prevent serious infections and save lives. But how often do you consider the underrecognized benefits of these vaccines—like how influenza vaccinations can be a cost-effective solution for both patients and the entire healthcare system? Joining Dr. Jennifer Caudle to discuss these underrecognized benefits and how we can educate patients about the benefits of influenza vaccination is Dr. Carolyn Bridges, Director of Adult Immunizations at Immunize.org.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kimberly McKeirnan, Pharm.D., BCACP
Vaccination rates are much lower in rural communities compared to other regions, which has a big impact on patients and the larger healthcare system as a whole. So what are some of the factors contributing to this disparity, and what strategies can we use to address them? Joining Dr. Charles Turck to discuss how we can increase vaccination rates in rural communities is Dr. Kimberly McKeirnan, Director of the Center for Pharmacy Practice Research at Washington State University.
Guest: Marc Riedl, MD, MS
Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl.
References:
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Guest: Marc Riedl, MD, MS
Prior to 2008, there were limited approved treatment options for hereditary angioedema (HAE) available in the United States, but today, there are several medications approved by the U.S. Food and Drug Administration for preventing and treating HAE attacks.1 In light of the number of therapies that have been approved in recent years and continued clinical advancements in HAE research, what do we need to consider when discussing these treatment options with our patients? Here to share those key considerations and important information on the HAE treatment landscape is Dr. Marc Riedl.
References:
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, Craig T, Davis-Lorton M, Frank MM, Li HH, Lumry WR, Zuraw BL. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3.
©2022 Takeda Pharmaceutical Company Limited. All rights reserved.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Musaddiq Khan
Clinical data continues to emerge on mRNA therapeutics and their applications. What do we need to know about this data, and are there any barriers to the broader application of these therapeutics? Dr. Charles Turck is joined by Musaddiq Khan, the Vice President of Therapeutic Area Solutions in the Customer Value Team at Medable, to dive into clinical trials for mRNA therapeutics.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Marc E. Agronin, MD
Guest: Anton Porsteinsson, MD
From expert specialists like internists and geriatric neuropsychiatrists to the patient themselves and their loved ones, there are a lot of individuals involved in an Alzheimer’s disease care team. So what are some best practices for collaborating and coordinating a patient’s care across all members of the team? Joining Dr. Charles Turck to share their perspectives are Dr. Marc Agronin from MIND Institute and Dr. Anton Porsteinsson from the University of Rochester.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Pam R. Taub, MD, FACC, FASPC
Guest: George L. Bakris, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
The FIDELITY pooled analysis findings demonstrated benefits in cardiovascular and kidney outcomes when nonsteroidal mineralocorticoid receptor antagonists (MRAs) were added to the mix. Tune in to hear Drs. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of chronic kidney disease, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Host: Charles P. Vega, MD
Guest: David J. Cennimo, MD, FACP, FAAP, FIDSA
Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.
Host: Charles P. Vega, MD
Guest: Paul G. Auwaerter, MD, MBA
Newer therapeutic options are now available to treat COVID-19. Don’t panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.
Host: Charles P. Vega, MD
Guest: Paul G. Auwaerter, MD, MBA
Newer therapeutic options are now available to treat COVID-19. Don’t panic! Drs. Charles Vega and Paul Auwaerter are here to help you successfully integrate these therapeutics into your practice. Find out how to identify patients that are at risk for severe disease and select the appropriate treatment for the patient in front of you.
Host: Charles P. Vega, MD
Guest: David J. Cennimo, MD, FACP, FAAP, FIDSA
Clinicians treating patients in outpatient, urgent care, and emergent care settings who encounter patients with mild to moderate disease are tasked with providing optimal care to prevent disease progression. Drs. Charles Vega and David Cennimo take us through the spectrum of COVID-19 disease and identify available treatment options for your high-risk patients.
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Host: Matt Birnholz, MD
Guest: David Canaday, MD
As we age, our immune system becomes weaker and is therefore unable to ward off infection as easily as in our younger years.1 This is particularly troublesome during flu season. In fact, the CDC’s Advisory Committee on Immunization Practices (ACIP) recently looked at flu vaccine data for adults aged 65 years and older, and they now recommend that this age group preferentially receive higher dose or adjuvanted vaccines over standard dose unadjuvanted vaccines when available.2 So what was the data that led to these updated recommendations? Joining Dr. Matt Birnholz to share those key findings and the role of adjuvanted vaccines like FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) in preventing influenza in older adults is Dr. David Canaday, Professor in the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University in Cleveland.
Avoid use in patients who have experienced any severe allergic reactions to any component of the vaccine. For more risk information please see below or consult the Full US Prescribing Information for FLUAD® QUADRIVALENT here.
References:
1. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659-666.
2. Centers for Disease Control and Prevention. Past seasons estimated influenza disease …
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sharon Sha, MD, MS
Guest: Anton Porsteinsson, MD
Alzheimer’s disease is considered to have a long preclinical course, meaning that changes in the brain occur without the presentation of any clinical symptoms. But unfortunately, diagnostic delays continue to exist even after symptoms appear. So what are the factors contributing to diagnostic delays, and how can we reduce this gap? Joining Dr. Charles Turck to discuss key strategies for early intervention in Alzheimer’s disease are Drs. Sharon Sha and Anton Porsteinsson.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
There are now multiple medical therapies available to facilitate weight loss in patients with type 2 diabetes (T2D). Learn who is the right patient, when these therapies should be started, and the right combinations and intensification strategies to sustain meaningful weight loss that can lower the risk of complications.
Guest: Kostas Lyketsos
The risk of Alzheimer’s disease increases substantially with age. In fact, about one in three adults aged 85 and older have dementia. So how do we screen for it, and what kind of impact can early detection have on our patients? Here to break down essential cognitive screening strategies for Alzheimer’s disease is Dr. Constantine Lyketsos, the Elizabeth Plank Althouse Professor for Alzheimer’s Research and Chair of Psychiatry at the Johns Hopkins Bayview Medical Center.
Guest: Peter Whitehouse, MD, PhD
What kind of impact can Alzheimer’s disease have on our patients, their caregivers, and the healthcare system as a whole? Here to help answer that key question is Dr. Peter Whitehouse, Professor of Neurology at Case Western Reserve University.
Guest: Peter Whitehouse, MD, PhD
Although obtaining specific statistics about the prevalence of Alzheimer’s disease can be difficult, what we do know is that its prevalence is increasing worldwide. With that in mind, Dr. Peter Whitehouse from Case Western Reserve University joins us to help uncover the unmet needs of patients, caregivers, and clinicians.
Guest: Francesca Taraballi, PhD
As mRNA therapeutics continue to evolve, what do we know about its potential in the treatment of infectious diseases? Dr. Francesca Taraballi from the Center for Musculoskeletal Regeneration at the Houston Methodist Hospital explores emerging mRNA therapeutics.
Guest: Rishi D. Naik, MD, MSCI
Colorectal cancer may be more prevalent than you think, underscoring the importance of colorectal cancer screening. Join us as we explore the latest screening recommendations and available modalities with Dr. Rishi Naik, Assistant Professor of Medicine in the Department of Gastroenterology, Hepatology, and Nutrition at Vanderbilt University Medical Center in Nashville, Tennessee.
Host: Jennifer Caudle, DO
Guest: Daniel R. Karlin, MD, MA
Digital tools have emerged as one of the newest therapeutic modalities for behavior modification in several chronic psychiatric diseases,1 such as major depressive disorder, chronic insomnia, and substance use disorders. But what exactly are these digital tools, and what does their use look like in practice? Joining Dr. Jennifer Caudle to answer those and other key questions regarding the use of digital tools in psychiatry is Dr. Daniel Karlin, Assistant Professor of Psychiatry at Tufts University in Boston and Chief Medical Officer at MindMed in New York City.
References:
- Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3:159.
August 2022 US.UNB.X.22.00018
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew N. Brams, MD
Since the use of digital tools in psychiatry and mental health treatment is already a reality, it’s important to know how to find the digital tool that best suits your and your patients’ needs and—perhaps even more importantly—how to encourage patients to use the tool. That’s why Dr. Charles Turck speaks with Dr. Matthew Brams, who shares the benefits of digital tools, the data he’s able to gain from them, how he talks to patients, and more.
July 2022 US.UNB.X.22.00009
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Matthew N. Brams, MD
Since the use of digital tools in psychiatry and mental health treatment is already a reality, it’s important to know how to find the digital tool that best suits your and your patients’ needs and—perhaps even more importantly—how to encourage patients to use the tool. That’s why Dr. Charles Turck speaks with Dr. Matthew Brams, who shares the benefits of digital tools, the data he’s able to gain from them, how he talks to patients, and more.
July 2022 US.UNB.X.22.00009
Host: Jennifer Caudle, DO
Guest: Daniel R. Karlin, MD, MA
Digital tools have emerged as one of the newest therapeutic modalities for behavior modification in several chronic psychiatric diseases,1 such as major depressive disorder, chronic insomnia, and substance use disorders. But what exactly are these digital tools, and what does their use look like in practice? Joining Dr. Jennifer Caudle to answer those and other key questions regarding the use of digital tools in psychiatry is Dr. Daniel Karlin, Assistant Professor of Psychiatry at Tufts University in Boston and Chief Medical Officer at MindMed in New York City.
References:
- Patel NA, Butte AJ. Characteristics and challenges of the clinical pipeline of digital therapeutics. NPJ Digit Med. 2020;3:159.
August 2022 US.UNB.X.22.00018
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Donna Ryan, MD
Guest: Juan Pablo Frías, MD
Dropping 15% or more of body weight has a greater disease-modifying effect than any other glucose-lowering intervention. Join Drs. Donna Ryan and Juan Pablo Frias as they discuss implementing an upstream intervention to weight loss and newer drugs (GIP agonists, GLP-1 receptor agonists, SGLT2 inhibitors) to help your patients experience improved effects earlier and for a longer duration. Tune in to find out how the novel dual GIP and GLP-1 receptor antagonist tirzepatide could fit into your therapeutic strategies.
Host: Cem Akin, MD, PhD
Guest: Jason Gotlib, MD, MS
It could take up to 7 years for a patient to be accurately diagnosed with systemic mastocytosis. Drs. Jason Gotlib and Cem Akin take us through the guidelines, diagnostic criteria, signs and symptoms, and the most important diagnostic tests for high-suspicion patients.
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Charles P. Vega, MD
Guest: Rajeev Raghavan, MD, M.Ed, FASN
Clinicians have a critical need for up-to-date knowledge related to anemia of CKD. Provide better care for your patients by learning about the importance of assessing and treating while considering the burdens of the disease, advances in our understanding of the pathophysiology of the disease, ways to fill the unmet needs of treatment with ESAs, and the status of potential new therapies. Tune in to keep up!
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Charles P. Gerba, MD
With rates of monkeypox continuing to rise, what do we need to know about this disease? And how easily can it spread from one person to another? Tune in to hear from renowned microbiologist, Dr. Charles Gerba, a Professor of Environmental Science at the University of Arizona as he explores these topics with Mario Nacinovich.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Julie Blatt, MD
Guest: Taizo Nakano, MD
PIK3CA-related overgrowth spectrum (PROS) refers to various clinical entities that share the same pathogenetic mechanism. These disorders are caused by somatic gain-of-function PIK3CA mutations. Diagnosis of PROS is often challenging and requires DNA sequencing of the affected tissue. PIK3CA genetic mutations vary greatly depending on the tissue being tested. PROS is not considered an inherited disease.
The road to a diagnosis of a rare disease can be a long, winding process. Because of its rarity, a wide spectrum of symptoms, and disease heterogeneity, patients may feel alone and as though they are the only ones with the disease. Management of PROS currently involves symptomatic treatment of its manifestations; an unmet need exists for targeted, systemic therapies.
Currently, there is no cure for PROS. This educational activity will assist the interprofessional care team to better understand, apply, and interpret advances in current and emerging evidence that will help bridge the gap toward faster adoption into patient care.
Host: Mario R. Nacinovich, Jr., MSc
Guest: Julia Bilinska, MD
Guest: Aatish Patel, MD
Monkeypox continues to spread around the globe, and its clinical manifestations can differ from what we’ve seen. What are the newest symptoms of this disease? Learn more about these manifestations from Drs. Aatish Patel and Julia Bilinska from Guy's and St. Thomas' NHS Foundation Trust in London as they talk about their research with Host, Mario Nacinovich.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Javier Morales, MD, FACP, FACE
Guest: Angela Yee-Moon Wang, MD, FACP, FACE
Diabetic nephropathy is one of the leading causes of end-stage renal disease (ESRD) and is associated with mortality and morbidity worldwide. Recent data on the use of nonsteroidal MRAs were presented at the European Society of Cardiology and other major meetings and were simultaneously published in major journals. Join our experts to explore these data and find out how you can better prevent the deterioration of renal function and improve cardiovascular outcomes in your patients across the spectrum of renal decline.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kenneth Cusi, MD, FACP, FACE
Not only is nonalcoholic steatohepatitis (NASH) the most common chronic liver condition worldwide, but it’s also becoming the number one cause of liver transplantation beyond hepatitis C. And with its growing prevalence and burden having no end in sight, Dr. Charles Turck speaks with Dr. Kenneth Cusi about how we can better recognize the symptoms of NASH in high-risk patient groups.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Jennifer Caudle, DO
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Guest: Gary Marshall, MD
It's well understood that annual vaccination is the best way to help reduce the high burden associated with influenza. And while most influenza vaccines available in the United States are produced in eggs, this presents some inherent challenges, which can lead to reduced vaccine effectiveness. Fortunately, alternative production processes can help us overcome those challenges, and to learn more, Dr. Jennifer Caudle speaks with Dr. Wendy Wright and Dr. Gary Marshall.
USA-CRP-22-0018 May 2022
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Nanette F. Santoro, MD
Tune out the noise and get to the heart of managing menopause and associated vasomotor symptoms. This program provides highlights from the 2022 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting. Join Drs. Nanette Santoro and Lee Shulman as they dive into the latest research, which could alter your current practice patterns and help your patients cool off.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Adrian F. Hernandez, MD, MHS
Recent clinical trial data and subsequent approval of novel therapies have expanded the treatment armamentarium. These advances have the potential to improve long-term patient outcomes, but also make the choice of therapy more complex. This activity aims to educate clinicians managing patients with HFrEF already on guideline-directed medical therapy (GDMT) who continue to be at high risk of rehospitalization to recognize the clinical characteristics of worsening heart failure and to select appropriate HF treatment strategies including novel classes of agents in heart failure.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Brian Smith, MD, MPH
Guest: Charlie Strange, MD
Screening for alpha-1 antitrypsin deficiency in patients with chronic obstructive pulmonary disease (COPD) plays an integral role in modern care algorithms. But screening is only the first step, however, as primary care physicians and pulmonologists must then work together to coordinate a patient’s care. Joining Dr. Charles Turck to share their perspectives on how we can better collaborate to detect and treat alpha-1 in patients with COPD are primary care physician Dr. Brian Smith and pulmonologist Dr. Charlie Strange.
Host: David Schulman, MD, MPH, FCCP
Guest: Andrew H. Limper, MD
Guest: Timothy A. Hernandez, MD
There are many barriers to reaching a definitive diagnosis for idiopathic pulmonary fibrosis (IPF). To learn more about these obstacles—and how we can overcome them—Dr. David Schulman from the American College of Chest Physicians joins Dr. Tim Hernandez from the University of Texas Health Sciences Center and Dr. Andrew Limper from the Mayo Clinic to discuss the diagnosis of IPF.
This is a non-promotional, non-CME disease state educational podcast produced in partnership with the American College of Chest Physicians and is supported by Three Lakes Foundation.
https://info.chestnet.org/bridging-specialties-timely-diagnosis-for-ild-patients
Guest: David C. Mares, MD
Since alpha-1 antitrypsin deficiency is prevalent among patients with chronic obstructive pulmonary disease (COPD), screening for alpha-1 is absolutely critical. However, diagnosing alpha-1 in patients with COPD can be challenging. That’s why pulmonologist and critical care specialist Dr. David Mares is here to share how we can overcome those challenges and the impact screening for alpha-1 may have on our patients with COPD.
Host: Jeffery D. Dunn, PharmD, MBA
Guest: Gary M. Owens, MD
Guest: Anita L. Nelson, MD
Are you ready to see what is on the horizon to more effectively navigate vasomotor symptoms (VMS)? Join Drs. Dunn, Owens, and Nelson as they discuss highlights from a symposium held at AMCP 2022 featuring the latest data on the impact of menopause and evolving treatments options. They provide guidance, context, and recommendations for the medical management of VMS beyond estrogen. The nonhormonal treatment options that are currently being studied represent a new horizon for both patients and payers.
Host: Richard Elion, MD
Sexual histories are a vital part of ensuring a patient’s well-being. Nonetheless, many providers are uncomfortable taking a sexual history for an individual who may be at increased risk for acquiring HIV. The ability to offer a preventative medication for HIV acquisition is a cornerstone for informed consent for sexual health. Join Dr. Richard Elion as he takes us through a patient-clinician dialogue demonstrating how to take a sexual history that is complete, respectful, and nonjudgmental.
Host: Christie M. Ballantyne, MD
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Joseph Saseen, PharmD, BCPS, BCACP, CLS
Guest: Karol Watson, MD, PhD
Managing patients with established CVD presents challenges in our practice every day. These patients may have had a prior stroke or MI and are at a very high risk of future life-threatening CV events. Join our expert faculty to hear the latest data on new and emerging statin adjuncts presented in a highly relevant and clinically applicable format. Barriers to the optimal management of ASCVD risk in many patient types (ethnicity/race/sex) will be addressed, and solutions to effectively manage such challenges in your everyday clinical practice will be provided.
Host: Richard S. Isaacson, MD
Guest: Michael Weiner, MD
Are you familiar with available and developing tools for assessing Alzheimer’s disease (AD)? Correctly using these tools can lead to a vital earlier diagnosis which can improve outcomes for our patients. Tune in to hear Dr. Richard Isaacson and Dr. Michael Weiner take us through some of these assessment tools and they ways in which they can help us reach a true diagnosis of AD.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Stephanie Martin, DO
How ready are you to go beyond simply ordering CBCs and recognizing anemia? Join Drs. Martin and Shulman as they discuss the latest developments in oral and IV iron therapies. Learn how you may take a more active role in managing iron deficiency anemia, focusing on abnormal uterine bleeding.
Participating in this activity will ensure that you are prepared to address the goals with your patients by improving access and adherence to efficacious and convenient therapies.
Host: Ahmad Masri, MD, MS
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
—Breaking News—Commentary on HCM-related Late-Breaking Abstracts presented at ACC.22 in April has been added to the start of the program. The rest of the program will cover the following topics: Why do we need new therapies in hypertrophic cardiomyopathy (HCM), and will newer and emerging cardiac myosin inhibitors improve the standard of care for patients with HCM? What differences can we expect regarding patient outcomes and quality of life with these new therapies? Join Dr. Ahmad Masri and Dr. Deepak Bhatt as they explore how newer cardiac myosin inhibitors go beyond traditional medical management (that only addresses the macro-pathophysiology and disease symptoms) to actually treat HCM at the cellular level.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Anjay Rastogi, MD, PhD
Defined as high potassium levels in the blood, hyperkalemia can be a life-threatening condition.1 Hyperkalemia is often associated with chronic kidney disease and can be silent or present itself with non-specific symptoms.1,2 However, there are challenges in managing hyperkalemia as a recurrent event.1,3 To help address these challenges, Dr Charles Turck discusses with Dr Anjay Rastogi, nephrologist and head of the CORE Kidney Program at UCLA, the burden of hyperkalemia and how potassium binders can help manage it.3,4 ©2022 AstraZeneca. All rights reserved. US-57356 Last Updated 2/22
Guest: Samira Farouk, MD
What can we expect to see at the upcoming Nation Kidney Foundation Spring Clinical Meeting? Dr. Samira Farouk from the Icahn School of Medicine at Mount Sinai shares what sessions she's looking forward to seeing on dialysis access, care coordination, and equitable patient care.
Guest: Vandana Niyyar, MD
What can we expect to see at the 2022 National Kidney Foundation Spring Clinical Meeting? Dr. Vandana Niyyar shares what sessions she plans on attending at this year's meeting, and what she's looking forward to seeing.
Host: Fuad El Rassi, MD
A common complication of sickle cell disease (SCD), vaso-occlusive crisis (VOC), is characterized by the sudden onset of severe pain and is the most common reason for hospital visits in patients with SCD. Vaso-occlusion is caused by the adhesion of sickled erythrocytes and leukocytes to the endothelium, resulting in vascular obstruction and tissue ischemia. In addition to severe pain, long-term complications of vaso-occlusion may include damage to muscle and/or bone, in addition to vital organs such as the liver, spleen, kidneys, and brain. Vaso-occlusion and VOCs are associated with decreased organ function and can result in life-threatening complications such as acute chest syndrome, pulmonary hypertension, renal failure, and stroke. SCD can also have a profound effect on the quality of life for children and adults.
With increased understanding of the pathophysiology of VOCs, novel therapies that target the pathologic process of vaso-occlusion may reduce cell adhesion and inflammation, leading to decreased incidence of VOCs and prevention of end-organ damage. This educational activity will review the burden of SCD, including VOCs, acute chest syndrome, and end-organ damage in adults and pediatric sickle cell patients, as well as efficacy and safety data of established and novel therapies that target SCD-related complications for …
Host: David A. Wohl, MD
Guest: Lisa Hightow-Weidman, MD, MPH
The CDC’s 2021 update to their PrEP guidelines recommend that PrEP should be offered to all individuals who want or need it. Although PrEP is both safe and extremely effective, persistence to PrEP in the long-term is low, at about 40% at 2 years. Join Drs. Wohl and Hightow-Weidman as they discuss the challenges associated with increasing PrEP uptake and how the emergence of a long-acting injectable PrEP formulation could result in improved long-term persistence.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Javier Morales, MD, FACP, FACE
There are several factors to consider when determining if insulin is the right treatment option for a patient with type 2 diabetes. And once a patient is prescribed insulin therapy, it’s just as important to consider the factors that might lead to nonadherence. That’s why Dr. Charles Turck speaks with Dr. Javier Morales about those factors and how we can improve our patients’ adherence to their insulin regimens.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Alexis McKee, MD
What communication strategies can we use to create personalized treatment plans and improve adherence among our patients with type 2 diabetes? That’s the exact question Dr. Charles Turck discusses with Dr. Alexis McKee, an Assistant Professor of Medicine in the Division of Endocrinology, Metabolism, and Lipid Research at the Washington University School of Medicine in St. Louis.
Host: Ahmad Masri, MD, MS
Guest: Steve R. Ommen, MD
What if a patient has fatigue, dyspnea, chest pain, palpitations, presyncope, left ventricular afterload, and diastolic dysfunction? Is it heart failure? Is it left ventricular hypertrophy due to arterial hypertension? Is it aortic stenosis? Did you even consider hypertrophic cardiomyopathy? Join Dr. Ahmad Masri and Dr. Steve Ommen as they discuss the challenges of HCM diagnosis and why you should get to know HCM!
Host: Rachel Caskey, MD, MAPP
Guest: Gwendolyn Ramirez
Vaccine hesitancy is a very challenging, and often tiring topic, for clinicians to address. Join Dr. Rachel Caskey in an engaging clinician-patient dialogue as she uses a dynamic and presumptive approach to overcome common vaccination challenges. What communication pearl will you use with your patients?
Host: George I. Papakostas, MD
Host: Larry Culpepper, MD, MPH
This Expert Exchange webcast is designed to help clinicians achieve better outcomes in patients with MDD who have an inadequate initial treatment response.
Host: John E. Anderson, MD
Guest: Scott Pilla, MD, MHS
One of the most serious side effects of diabetes, hypoglycemia can lead to severe consequences, and keeping up with the latest in care can help us prevent this complication. To share the latest updates, Dr. John Anderson is joined by Lead Researcher Dr. Scott Pilla to share insights from his recent studies on hospital utilization and primary care communication for patients with diabetes.
Host: Jane Mast, PA-C, MPAS, DMSc
Guest: Douglas DiRuggiero, DMSc, PA-C
Join podcast guest Doug DiRuggiero, PA, a certified physician assistant and the founding president of Georgia Dermatology Physician Assistant Society, and host Jane Mast, a Novartis Medical Director and certified physician assistant in a discussion focusing on the diagnosis and management of psoriasis in pediatric and adolescent patients.
During their discussion, they address the following topics:
- Important clinical features of psoriasis in children and adolescents and how they may differ from those in adult patients
- Communication strategies to use when talking to parents about their child’s psoriasis
- Psychosocial impact of psoriasis
- Approaches to management
This podcast is sponsored by Novartis Pharmaceuticals Corporation and the podcast guest is being compensated for his time.
© 2021 Novartis Pharmaceuticals Corporation
Host: Rahul N. Khurana, MD
Guest: Jennifer K. Sun, MD, MPH
The results from the Protocol W and PANORAMA clinical trials have sparked a lot of talk in the retina community about what the data really mean. So how should physicians interpret these data, and what is changing for their patients with diabetic retinopathy?
Find out in this activity as Dr. Rahul Khurana and Dr. Jennifer Sun review the findings from both trials and discuss if treatment with anti-VEGF really improves outcomes for patients with moderate to severe NPDR.
Host: Ruth S. Weinstock, MD, PhD
Guest: Susan B. Bressler, MD
Guest: Mark Dunbar, OD, FAAO
With the increasing prevalence of diabetes in the United States, more individuals are at risk of losing their vision due to diabetic retinopathy every day. Fortunately, research is improving our understanding of this disease. But what does the latest information mean for our patients?
Hear Dr. Susan Bressler, Dr. Mark Dunbar, and Dr. Ruth Weinstock share their perspectives as multidisciplinary specialists treating these patients. Find out what the evidence shows and how timely referral, early diagnosis, and appropriate treatment can prevent the vision-threatening complications of diabetes.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Andrew F. Alexis, MD, MPH
There is often a delay in the diagnosis of psoriasis and/or psoriatic arthritis for people with skin of color. Among the multiple factors that cause this disparity are a low index of suspicion for such a diagnosis in skin of color and a lack of familiarity with the morphology of these conditions in richly pigmented skin. Join Drs. William Mencia and Andrew Alexis as they address pathways to overcoming these systemic and experiential healthcare barriers.
Host: Sergio Schwartzman, MD
Guest: April W. Armstrong, MD, MPH
Guest: Philip J. Mease, MD, MACR
Integrating routine assessments of psoriatic arthritis (PsA)-related structural progression has proven challenging in clinical practice. Join Drs. Sergio Schwartzman, Philip Mease, and April Armstrong as they discuss evidence that frequent monitoring of PsA structural progression permits earlier intervention with effective therapies as well as provides indications for when to switch to another class of agent. They also address which therapeutic agents have been shown to impact PsA structural progression in clinical trials and provide insight into how best to incorporate collaborative treatment strategies across disciplines. These practices are likely to improve outcomes for patients with PsA, so be sure to stay informed.
Host: Muhammad Adrish MD, MBA, FCCP, FCCM
Guest: Navitha Ramesh, MD, FCCP
Inhalers are one of the most common methods of delivery for the treatment of COPD, but is it the best option for all of our patients? Associate Professor of Pulmonary Critical Care at Baylor College of Medicine, Dr. Muhammad Adrish, reviews LAMA use for COPD patients with Dr. Navitha Ramesh, Assistant Professor at Drexel University College of Medicine.
This episode is produced in partnership with the American College of CHEST Physicians and is sponsored by Viatris Inc.
Host: Carol Wysham, MD
Guest: Deepak Vashishth, PhD
Guest: Bowen Wang
Can we predict when a patient with COVID-19 requires hospitalization? To answer this question, Dr. Carol Wysham is joined by Dr. Deepak Vashishth and Mr. Bowen Wang from the Rensselaer Polytechnic Institute to share data from their study on the impact of glycemic levels and common medications on COVID-19 severity in patients with type 2 diabetes.
Host: John J. Russell, MD
Guest: Benjamin Abramoff, MD, MS
Once a patient is discharged from the hospital after battling COVID-19, the war they face with this disease may not be over. In fact, many patients continue to experience long-term effects, which is why some institutions have formed clinics that are solely dedicated to caring for these patients. To learn more about how one such clinic is helping patients manage these devastating effects, Dr. John Russell speaks to physiatrist Dr. Benjamin Abramoff from the Post-COVID Assessment and Recovery Clinic at Penn Medicine in Philadelphia.
Host: Hector O. Chapa, MD, FACOG
Guest: Kellie Moore, ND
We've all heard the phrase "you are what you eat." But are we now at a point where science is backing up that old saying? To find out how our diet can impact our cognitive function and mood, Dr. Hector Chapa speaks with naturopathic physician Dr. Kellie Moore. Together, they’ll review the foods that we should eat versus avoid and the resources we can use to help our patients have a healthy mind and body.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Ayman Al-Hendy, MD
Surgery has long been the default choice when managing uterine fibroids and endometriosis. However, over the past few years, reliable and durable medical interventions have emerged, notably GnRH antagonist therapy. Clinical trial data for GnRH antagonists highlight both their safety and efficacy for a broad demographic of patients. Join Drs. Lee Shulman and Ayman Al-Hendy as they discuss the “how” and the “why” of a paradigm shift that is occurring, changing our focus from surgery to first-line medical intervention for uterine fibroids and endometriosis.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Donald Middleton, MD
Influenza causes considerable morbidity and mortality in children. In fact, the CDC estimates that from the 2010-2011 season to the 2019-2020 season, seasonal flu-related hospitalizations among children younger than 5 years old have ranged from 7,000 to as high as 26,000 every year.1 This is a sobering reminder of the pivotal role vaccination plays in preventing influenza disease, and now, recent safety and immunogenicity data has led to the expanded age indication for the cell-based vaccine FLUCELVAX QUADRIVALENT. Explore that data and what this approval means for patients 6 months of age and older with Drs. Charles Turck and Donald Middleton.
- Centers for Disease Control and Prevention. Flu and young children. https://www.cdc.gov/flu/highrisk/children.htm. Accessed December 22, 2021
USA-QIVc-21-0169 December 2021
Host: John J. Russell, MD
Guest: Leana S. Wen, MD, MSc
From immigrant child to public health leader, emergency physician and medical expert Dr. Leana Wen sits down with Dr. John Russell to share her journey. Together, they’ll discuss the personal experiences that have framed her career.
Host: Hector O. Chapa, MD, FACOG
Guest: Linda Bradley, MD
Medical commentators have stated that medicine as a profession is sick. So what can medicine do to change and better impact the community? That’s the exact question Dr. Hector Chapa explores with Dr. Linda Bradley from Case Western Reserve University. Together, they’ll discuss why social determinants of health exist, the impact they have on communities, and even more importantly, how we can combat them.
Host: John E. Anderson, MD
Guest: Elizabeth A. Beverly, PhD
Current treatment strategies for diabetic patients focus on behavioral and clinical targets alone, but can shared experiences and peer support improve care? To learn more about this, Dr. John Anderson talks to Dr. Elizabeth Beverly from the Ohio University Heritage College of Osteopathic Medicine to discuss her recent study on positive experiences for patients living with type 1 or type 2 diabetes.
Host: Peter Rossing, DMSc, MD
Guest: Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
Guest: Matthew R. Weir, MD
Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.
In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Joseph Marek, MD
Sudden cardiac death is rare in younger patients, but it remains one of the leading causes of death in young athletes. To learn more about this, Dr. Alan Brown is joined by Dr. Joseph Marek, Clinical Cardiologist and Senior Medical Director of Cardiopulmonary Service at Advocate Medical Group, to share how his foundation, Young Hearts 4 Life, is working to increase awareness for sudden cardiac arrest and provide young athletes resources.
Host: John J. Russell, MD
Guest: R. Scott Turner, MD, PhD
Alzheimer’s disease (AD) is an irreversible, age-related, neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. It is the most common cause of dementia worldwide and its’ prevalence continues to grow in part because of the aging world population. AD is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria including fluid and imaging biomarkers. Until recently, current therapies were limited to delaying cognitive decline in some patients, but not treating the underlying causes of the disease nor halting the progression of the disease. This program discusses recent advances in our understanding of the clinical evaluation for early and accurate diagnosis, newly approved and emerging disease-modifying therapies, as well as non-pharmacological strategies for the management of patients with AD.
Host: John J. Russell, MD
Guest: Jessica Malaty Rivera, MS
Social media and the ability to quickly spread information across the internet has allowed misinformation surrounding COVID-19 vaccines and the disease itself to spread like wildfire. But the good news is that when armed with effective counseling strategies and data from initiatives like the COVID-19 Tracking Project, we as clinicians can help stop the spread of harmful conspiracies and myths. Joining Dr. John Russell to talk about those essential strategies and the COVID-19 Tracking Project is infectious disease epidemiologist Ms. Jessica Rivera.
Host: Jayanth Sridhar, MD
Guest: Avni P. Finn, MD, MBA
Are you aware of the latest data that adds to our understanding of the management of diabetic retinopathy (DR)? Listen in as Dr. Avni Finn and Dr. Jay Sridhar discuss what those data are and the impact they have on the early referral and timely treatment of patients with DR. Make sure you’re properly using all of the resources in your armamentarium to save your patients’ sight.
Host: Murray Epstein, MD
Guest: Gates B. Colbert, MD, FASN
Determining the optimal strategies for treating patients with chronic kidney disease (CKD) can be challenging. After decades of waiting, exciting and rapid progress in renin-angiotensin-aldosterone system (RAAS) inhibition is being made, but these therapies can lead to hyperkalemia. The trick is to sustain optimal therapy in the patient without interruption or reduction. Are you familiar with novel potassium binders and recent changes in guideline-directed medical therapy surrounding their use? Tune in because these resources are offering new therapeutic opportunities for your patients with CKD.
Join Drs. Murray Epstein and Gates Colbert to ensure you’re up to date on the latest treatment options for your patients with CKD.
Host: Michael E. Thase, MD
Guest: Sagar V. Parikh, MD
Depression can cause a multitude of symptoms, many of which are associated with impairment that, if not treated appropriately, can go on for months or even years. With traditional antidepressants having a longer time to onset, the role of rapid-acting agents can greatly improve the quality of life for patients with major depressive disorder (MDD). Dr. Michael Thase and Dr. Sagar Parikh discuss the clinical diagnosis of MDD and the role of emerging neuroactive steroids. Tune in and fasten your seat belt for faster results!
Host: Jonathan C. Routh, MD, MPH, FAAP
Guest: Benjamin M. Whittam, MD, MS, FAAP, FACS
This Expert Exchange webcast is designed to enhance clinicians’ awareness of advances in the pharmacotherapeutic armamentarium for treating NDO in the pediatric population.
View the Advances in the Treatment of Neurogenic Detrusor Overactivity Clinical Compendium here: https://cdn.reachmd.com/uploads/clinicalcompendium_ndo_v2_final.pdf
Host: Diana Shechtman, OD, FAAO
Guest: Carolyn E. Majcher, OD, FAAO
When it comes to diabetic retinopathy, studies and new data are constantly being published. Are you up to date with the progress being made? Join Dr. Diana Shechtman and Dr. Carolyn Majcher for a discussion on the latest data around the treatment of nonproliferative diabetic retinopathy and how these advances affect the management of your patients.
Host: William Mencia, MD, FACEHP, CHCP
Guest: Eliza B. Geer, MD
The primary goals in the medical management of Cushing’s disease are to normalize cortisol levels and reduce or eliminate the associated comorbidities, physical features, and symptoms for our patients. With recently approved therapies and more in development, it really is an exciting time in this treatment space! Tune in to hear Dr. Eliza Geer discuss novel medical options and how we should remember the importance of looking at patient outcomes to make sure we’re addressing Cushing’s disease holistically.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Guest: Norman E. Lepor, MD
Tune in to hear Dr. Norman Lepor from the UCLA Geffen School of Medicine discuss the role of LDL-C and comorbidities in atherosclerotic cardiovascular disease (ASCVD) risk assessment as well as the limitations of statin treatment.
10/21 121913
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Maria Trent, MD, MPH, FAAP, FSAHM
Dr. Mimi Secor is joined by Dr. Maria Trent to discuss mycoplasma genitalium (MGen), how we can better understand this infection and help reduce our patients' risk of it.
Host: Clete A. Kushida, MD, PhD
Guest: Lois E. Krahn, MD
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Andrea S. Lukes, MD, MHSc, FACOG
By 50 years of age, 70% to 80% of women are affected by uterine fibroids, and nearly 10% of women are affected by endometriosis. Clinical trial data demonstrate that GnRH antagonist therapy can dramatically impact pain and bleeding and improve results across all EHP-30 domains. Join Drs. Lee Shulman and Andrea Lukes as they dive into these data and offer strategies to help you better incorporate patient-centric medical management for uterine fibroids and endometriosis into your clinical practice.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Host: Mikhail Kosiborod, MD
Guest: Javed Butler, MD, MBA, MPH
Guest: Matthew R. Weir, MD
Renin-angiotensin-aldosterone system inhibition (RAASi) is the foundation of guideline-directed medical therapy (GDMT) for heart failure patients. However, due to practice gaps, a significant proportion of the population requiring its use do not experience the benefits of RAASi therapy, which is especially true for patients with comorbid conditions. Hyperkalemia is a common adverse effect of RAASi therapy that needs to be anticipated and mediated so that the optimal dosing of necessary medications can occur. Maximizing GDMT in the face of hyperkalemia remains a key clinical challenge that, if not handled properly, can result in increased morbidity and mortality.
In this activity, Drs. Javed Butler, Mikhail Kosiborod, and Matthew Weir review a patient case and discuss different treatment approaches to optimize GDMT while managing hyperkalemia. Tune in to make sure you’re doing all you can to improve outcomes for your patients with heart failure and comorbid conditions.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Manish Thapar, MD, AGAF, FAASLD, FACG
Acute hepatic porphyria (AHP) is a rare genetic condition characterized by severe, diffuse abdominal pain and a broad range of seemingly unrelated symptoms. AHP presents differently in each patient, with symptoms that mirror those of more common conditions, making it difficult to diagnose. Although AHP can be misleading, it can be easy to detect once you know what to look for. Joining Dr. Charles Turck to discuss AHP signs and symptoms and when a doctor should consider AHP in a patient is porphyria expert Dr. Manish Thapar, gastroenterologist and associate professor of medicine in Philadelphia.
©2021 Alnylam Pharmaceuticals, Inc. All Rights Reserved. AS1-USA-01069
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Not all patient subgroups respond to medication the same way, making equal representation in clinical trials essential. Dr. Javed Butler is joined by Dr. Ileana Piña, a Heart Failure Cardiologist and Clinical Professor of Medicine at Central Michigan University, to talk about how we can improve diversity in cardiovascular clinical trials.
Guest: Peter Goadsby, MD, PhD, DSc
Guest: Kathleen B. Mullin, MD
Women with migraine have unique needs that often remain undermanaged. Have you taken a critical look at the standard of care and how current treatment strategies have recently shifted? Groundbreaking research on the calcitonin gene-related peptide (CGRP) pathway has led to the development of new medications that act on the specific cascade of inflammatory response associated with migraine. Also called gepants, the CGRP receptor antagonists confer clinical benefit to patients who seek better control of their migraines.
Tune in to this Women’s Health 2021 program to hear our experts, Drs. Peter Goadsby and Kathleen Mullin, discuss the diagnosis of migraine with a focus on the recent evolution of acute and preventive treatment strategies and the role of gepants. Are you doing all you can to ensure that your patients’ needs are optimally addressed?
Host: Anita H. Clayton, MD
Listen in as Dr. Anita Clayton takes us through the importance of screening for postpartum depression (PPD) and reaching an early diagnosis in the perinatal and postnatal stages of pregnancy. This Women’s Health 2021 lecture also covers the exciting new agents that are targeted specifically for PPD. Find out how they compare to the traditional antidepressants and how they can improve the quality of life for your patients with PPD.
Host: Anita L. Nelson, MD
How confident are you in determining which of your patients with endometriosis are suitable candidates for medical intervention? Do you ask about each patient’s goals and preferences? Have you heard about the paradigm shift occurring in the medical management of endometriosis?
While medical management of endometriosis is often a secondary consideration to surgery, it should often be the first line of treatment. Join Dr. Anita Nelson as she discusses long-standing and novel medical strategies for managing endometriosis. Find out how you can use shared decision-making strategies to help you provide more options to your patients. Join us and take an important first step that can improve outcomes and quality of life for your patients while enabling them to make educated decisions about their immediate and long-term treatment.
Host: Lee P. Shulman, MD, FACMG, FACOG
Guest: Erica E. Marsh MD, MSCI, FACOG
Hear from Dr. Erica Marsh and Dr. Lee Shulman as they discuss the burden, prevalence, and treatment of uterine fibroids and endometriosis and the disproportionate impact these conditions have on vulnerable populations. Learn how to prioritize early diagnosis and treatment to improve outcomes for your patients; as well as evaluating barriers to proper diagnosis and treatment
Our experts offer strategies to guide discussions beyond surgical treatment approaches to include pharmacotherapeutic options such as GnRH agonists and new oral GnRH antagonists. Open communication with patients allows them to carefully consider symptom severity, risks, and fertility preferences to optimize treatment outcomes and patient satisfaction. Tune in to make sure that you’re really doing all you can for your patients.
Host: Anita L. Nelson, MD
In this Women’s Health 2021 lecture, Dr. Anita Nelson discusses why uterine fibroids are such a high priority for both women and their clinicians. Listen in as she shares strategies to engage patients in discussions about their fibroid symptoms and their preferences for treatment. Dr. Nelson also evaluates the latest evidence on the mechanisms of action, safety, and efficacy of the newer class of therapies that are now available and can improve the quality of life for women with fibroids.
Host: Matt Birnholz, MD
Guest: Ripal Patel, MD, MPH
Locum tenens can take you on an exciting journey, but you may encounter a few horror stories along the way. Joining Dr. Matt Birnholz to share his own challenging experiences—and how we can avoid them—is Dr. Rip Patel, founder and lead for Mercision Emergency Medicine, and Assistant Professor at the Baylor College of Medicine in Houston, Texas.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Mark Blatter, MD
Despite their crucial role in preventing seasonal influenza, traditional influenza vaccines may not be providing as much protection as we thought, leading researchers to take a look at different methods of vaccine production, specifically cell-based flu vaccine production. Here with Dr. Charles Turck to discuss influenza prevention and the latest evidence supporting a cell-based vaccine option is Dr. Mark Blatter.
USA-QIVc-21-0146 November 2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Hassan Bencheqroun, MD
Evaluating the need for therapy escalation can be challenging. So joining Dr. Charles Turck to help us understand how to escalate treatment for patients with chronic obstructive pulmonary disease is Dr. Hassan Bencheqroun, Assistant Professor of Medicine at the University of California Riverside School of Medicine.
This is a non-promotional, non-CME disease state disease education podcast series brought to you by American College of CHEST Physicians in collaboration with and paid for by GSK.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Maria Trent, MD, MPH, FAAP, FSAHM
Dr. Mimi Secor is joined by Dr. Maria Trent, Chief of the Division of Adolescent and Young Adult Medicine at Johns Hopkins School of Medicine, to discuss diagnosing and treating antibiotic resistant MGen.
Host: Michael E. Wechsler, MD, MMSc
Guest: Eileen Wang, MD, MPH
In this session, National Jewish Health faculty experts will discuss a new paradigm of severe asthma pathophysiology and potential treatment targets that may impact patients with non-allergic and non-eosinophilic as well as eosinophilic severe asthma. This session will explore new understanding of the immunology of severe asthma, new potential targets for treatment, and emerging data on novel therapies that may improve outcomes for your patients with severe asthma.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Joshua Ofman, MD, MSHS
Despite significant advancements in therapeutics, the oncology community has not yet been able to declare victory in the “war on cancer.” In fact, about 40 percent of Americans receive a cancer diagnosis in their lifetime, amounting to over 600,000 American deaths on average every year or nearly 1,700 loved ones a day. But could hope be on the horizon thanks to technological developments like multi-cancer early detection (MCED)? Find out with Dr. Paul Doghramji and Dr. Joshua Ofman, a public health services researcher as well as the Chief Medical Officer and Head of External Affairs at GRAIL.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Guest: Cem Akin, MD, PhD
Host: Jennifer Caudle, DO
What is the risk of anaphylaxis following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19)? Are you familiar with the role of serum tryptase testing in patients with a suspected anaphylactic reaction? Expert faculty, Dr. Cem Akin, discusses serum tryptase testing and its importance in assessing anaphylaxis in response to COVID-19 vaccination. This moderated discussion is enhanced with animation, key takeaways, and support slides to provide an engaging learning experience.
Serum tryptase plays an important diagnostic role in the setting of mast cell activation resulting from a variety of causes, including mastocytosis and SARS-CoV-2 vaccination. Emergency medicine specialists, allergists, and primary care providers serve as the first-line responders to patients experiencing the effects of mast cell activation. The measurement of tryptase levels helps confirm diagnoses and inform management decisions for these life-threatening disorders. This education enables multidisciplinary clinicians to identify patients at risk of mast cell activation due to a variety of causes and employ appropriate use of tryptase testing across acute and follow-up care settings.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Hector O. Chapa, MD, FACOG
Guest: Shay Walters
Mrs. Shay Walters was just 15 years old when she first became involved with substance use, and it wouldn’t be until years later that she would finally overcome her addiction. Her story, however, is far from the only one like it. Millions of Americans currently struggle with addiction, which is why she founded the “From Prison to Purpose” Facebook group that now has half a million followers. And to further help those who are trapped under drug addiction and even the clinicians who care for those patients, Mrs. Walters joins Dr. Hector Chapa to share her inspiring story.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Robert J. Chilton, DO
Guest: John R. Nelson, MD, FACC, FNLA, FASNC
Join Drs. Chilton and Nelson as they discuss recent omega-3 fatty acid (OM-3) outcomes trial results and how to apply those results along with evidence-based guidelines to reduce ASCVD risk. Tune in to hear about the use of OM-3s including dietary supplement OM-3s that are readily available in pharmacies and online, so you can keep your patients informed!
Host: Michael Greenberg, MD
Guest: Howard K. Steinman, MD
We always want patients to leave our office feeling happy, healthy, and pleased with their care, but unfortunately, that isn't always the case. The good news, however, is that the acronym BLAST can help guide our conversations with patients who are less than satisfied with their care. Joining Dr. Michael Greenberg to break down this five-step method for speaking with displeased patients is Dr. Howard Steinman, a board-certified dermatologist and fellow of the American College of Mohs Surgery.
Host: David L. Eisenberg, MD, MPH, FACOG
Many women prefer to use a nonhormonal contraceptive. They also want the freedom to self-administer on demand and want assurances that the contraceptive is safe, effective, and has received FDA approval. One such contraceptive is a self-administered, hormone-free gel that functions as a vaginal pH modulator. Join Dr. David Eisenberg as he describes the evolution of this vaginal pH modulator and the clinical trials leading to FDA approval. Even more significant is patient acceptance, which was remarkably high for this contraceptive. In fact, approximately 9 out of 10 women participating in the clinical trials indicated they would continue using the vaginal pH modulator and also recommend this novel method to their friends.
Host: Louis Kuritzky, MD
Guest: Karl Doghramji, MD, FAASM, DFAPA
Guest: Julie Flygare, JD
Guest: Phyllis C. Zee, MD, PhD
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
Guest: Gregory Pokrywka MD, FACP, FNLA, FASPC, NCMP
Guest: Karol Watson, MD, PhD
Join us to discover optimal ways to identify women at risk or with atherosclerotic cardiovascular disease (ASCVD). In this Women’s Health 2021 lecture, our experts, Dr. Gregory Pokrywka and Dr. Karol Watson, dive deeper into evidence-based approaches to assess and manage ASCVD in women. They discuss topics from lifestyle modifications to recent clinical trial data on the use of omega-3 fatty acids for ASCVD event reduction.
Host: Paul Nyirjesy, MD
The global burden of acute vulvovaginal candidiasis (VVC) and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved solutions and quality of care for affected women. Join Dr. Paul Nyirjesy as he dissects the barriers to managing VVC and RVVC in your clinical practice and provides both diagnostic and therapeutic guidance inclusive of newly emerging and novel agents. These agents have unique qualities that may well represent a significant step forward in how you manage this challenging infection.
Guest: Madhukar H. Trivedi, MD
Guest: Steven Shoptaw, PhD
Join Drs. Madhukar Trivedi and Steven Shoptaw as they discuss the evolving landscape of pharmacologic intervention for methamphetamine use disorder. Their focus will be on evidence from the ADAPT-2 clinical trial supporting the combination of extended release naltrexone and high dose bupropion to reduce methamphetamine use for patients with moderate to severe methamphetamine addiction. These important data from ADAPT-2 offer a significant therapeutic advance for methamphetamine use disorder that can be taken into the clinic.
Host: Brooke M. Faught, DNP, WHNP-BC,NCMP, IF
Our patients express a number of misperceptions about combined hormonal non-LARC contraceptives such as the contraceptive patch, vaginal rings, and oral contraceptive pills. How well do you explain the advantages and disadvantages of these different options to your patients? How often have you prescribed what appeared to be a good contraceptive method for your patients only to have them be dissatisfied and become nonadherent?
Join Dr. Brooke Faught in this Women’s Health 2021 lecture as she tackles these issues and offers insights into how to discuss the full range of combined hormonal non-LARC contraceptive options with your patients using shared decision-making strategies. Remember, each patient’s needs, goals, and cultural background are important factors in a patient-centric approach to the choice of contraception.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Ricardo Franco, MD
Guest: Charles P. Vega, MD
Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direct-acting antiviral (DAA) therapies — primary care providers (PCPs) will be well equipped to step up and provide comprehensive HCV care and cure. This educational activity offers practical tips and tactics to prepare PCPs for their central role in eliminating HCV.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: George L. Bakris, MD
Guest: Rajiv Agarwal, MBBS, MD, FASN, BRCU
Guest: Bertram Pitt, MD
Two HOT LINE sessions presented at the ESC Congress 2021 may change the way you manage your patients with diabetes and CKD as you work to prevent their progression to ESRD and improve their cardiovascular outcomes. Drs. Rajiv Agarwal, George Bakris, and Bertram Pitt review data from the FIGARO-DKD trial and the FIDELITY Analysis to explore the evolving role of mineralocorticoid receptor antagonists (MRAs) as part of the overall treatment plan for patients with diabetes and CKD. Don’t miss this potentially practice-changing session!
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Host: George L. Bakris, MD
Guest: Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
Guest: Robert Toto, MD
When treating patients with heart failure and chronic kidney disease, RAASi therapy should be continued if at all possible. One thing to keep in mind is that an elevation in serum creatinine does not always represent acute kidney injury. In this activity, Drs. George Bakris, Biykem Bozkurt, and Robert Toto examine a case study and discuss transient changes in serum creatinine with hyperkalemia. Join us to find out how and why you should avoid RAAS blockade interruption in these patients.
Host: John E. Anderson, MD
Guest: Simon Heller, MD
Dr. Simon Heller, a Professor of Clinical Diabetes at the University of Sheffield, and honorary consultant physician with the NHS Foundation Trust in the United Kingdom, reflects on the steps we can take to prevent severe hypoglycemia and reduce cardiovascular risk in diabetic patients.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
John Anderson joins fellow Diabetes Discourse hosts John Buse and Carol Wysham to explore exciting clinical trial results presented at this year's Scientific Session of the American Diabetes Association.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Dustin Sulak, DO
Dr. Dustin Sulak, an integrative medicine physician specializing in osteopathy, mind-body medicine, and medical cannabis, talks about the impact of cannabis on the cardiovascular system.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Dustin Sulak, DO
The medical community continues to voice the medical benefits of cannabis. What do we need to know about them? Dr. Charles Turck discusses the benefits of medical cannabis with Dr. Dustin Sulak, an integrative medicine physician with a special focus on osteopathy, mind-body medicine, and medical cannabis.
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Post-exposure influenza prophylaxis should be a top-of-mind discussion with patients receiving an influenza diagnosis. Unfortunately, it remains an underused means to reduce secondary infections in at-risk households. Join Drs. Cassandra Donnelly and Charles Vega as they examine an extended patient case and offer practical strategies to overcome common clinical barriers surrounding post-exposure influenza prophylaxis, including how to match the right patient with the right antiviral treatment.
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.
Guest: Susan Butler-Wu, PhD, D(ABMM), SM(ASCP)
Dr. Susan Butler-Wu, Associate Professor of Clinical Pathology and Director of Medical Microbiology at LAC+USC Medical Center, investigates the differences—and highlights the benefits—of PCR versus antigen testing for COVID-19.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Guest: Heval M. Kelli, MD
Guest: Alan Amedi
What do we need to know about a career in cardiology? Dr. Alan Brown meets with Dr. Heval Kelli, a cardiologist at the Northside Hospital in Atlanta, and Alan Amedi, a first-year medical school student at Emory University, to explore their experiences in the cardiology field and learn about their perspectives on training.
Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: Leslie Cho, MD
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
Host: George L. Bakris, MD
Guest: Biff F. Palmer, MD
In this case-based activity, Drs. George Bakris and Biff Palmer discuss the benefits of RAAS inhibitors in the patient diagnosed with diabetes, hypertension, and chronic kidney disease. They review the importance of titrating RAAS inhibitors to the highest tolerated recommended dose and identify obstacles to optimizing the dosing of these therapies in patients with comorbidities. They also discuss the use of potassium binders for the management of hyperkalemia as an alternative to discontinuing RAASi therapy.
Host: Cassandra B. Donnelly, DO
Guest: Charles P. Vega, MD
Antiviral agents are underutilized against influenza in clinical practice, a failure that places many patients, especially those with comorbidities, at high risk for influenza-associated complications. Join Drs. Cassandra Donnelly and Charles Vega as they explore management strategies for patients with symptomatic influenza, compare and contrast clinical applications for the available antiviral agents, and reflect upon the increasing use of these agents as post-exposure influenza prophylaxis.
Host: Paul W. Armstrong, MD
Guest: Justin Ezekowitz, MD, MBBCh, MSc
Is it possible to reduce the nearly 60% one-month rehospitalization rates in patients with worsening heart failure? Dr. Paul Armstrong and Dr. Justin Ezekowitz discuss new therapeutic combinations including soluble guanylate cyclase (sGC) stimulators, as well as the practical applications of new evidence that was presented at the 2021 annual ACC meeting that may change how physicians approach treating their patients with worsening heart failure. Don’t miss out on new information about how sGC stimulators may benefit your patients.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lincoln Nadauld, MD, PhD
Current cancer screening methods like mammograms, colonoscopies, and CT scans are all effective in detecting cancers, but they don’t always detect cancers as early as we’d like them to, resulting in missed and delayed diagnoses. Could new technology like multicancer early detection (MCED) be the answer to addressing current unmet needs in cancer screening? Find out with Dr. Charles Turck and Dr. Lincoln Nadauld, an oncologist and the Vice President and Chief of Precision Health and Academics at Intermountain Healthcare.
Host: Fernando J Martinez, MD, FCCP
Guest: Navitha Ramesh, MD, FCCP
At least 50 percent of our patients with asthma continue to experience uncontrolled asthma, and they remain at risk of asthma exacerbations, which can be serious. To learn more about the impacts of uncontrolled asthma, Dr. Fernando J. Martinez sits down with Dr. Navitha Ramesh, who discusses how we can better diagnose, assess, and treat this condition.
A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline
Guest: Barbara Van Der Pol, PhD, MPH
Dr. Barbara Van Der Pol, a Professor of Medicine in Infectious Diseases at The University of Alabama at Birmingham and Scientist at the Center for Women’s Reproductive Health briefly discusses how rapid testing could impact the treatment landscape for sexually transmitted infections.
Host: Hector O. Chapa, MD, FACOG
Guest: Julio M. Jimenez
While many practicing physicians are aware of Mendelian genetics, epigenetics is a much more complicated field of study. What can this field of genetics tell us about chronic health conditions? Dr. Hector Chapa joins Dr. Julio Jimenez, a licensed chiropractic doctor, to discuss the importance of understanding epigenetics.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
There is clinical trial-supported evidence for the use of renin-angiotensin-aldosterone system inhibitors (RAASi) in patients with heart failure and reduced ejection fraction. RAASi therapy improves both morbidity and mortality outcomes, and its use is now recommended in published guidelines. However, the achievement of target dosing is often limited or interrupted due to the development of hyperkalemia.
In this case-based activity, Drs. Javed Butler and Ileana Piña discuss the importance of optimizing RAASi therapy in patients with heart failure and how the use of potassium binders can help accomplish this goal. They will also review the risks and benefits of potassium binders, in addition to both short- and long-term use of these agents in the treatment of patients with heart failure.
Host: Jerome Lisk, MD
Guest: Merle Diamond, MD
With migraine as a major global health problem that affects over 10% of the population, approximately 1 billion globally, and about 12% in the US, now more than ever it’s vital that healthcare professionals have a deep understanding of the role of the calcitonin gene-related peptide (CGRP) and its receptor in migraine pathophysiology1,2,3. That’s why Dr. Merle Lea Diamond joins Dr. Jerome Lisk to review that and more.
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Lancet. 2018;392:1789-1858.
- Lipton RB, et al. Neurology. 2007;68:343-349.
- Lassen LH, et al. Cephalalgia. 2002;22:54-61.
USA-334-84583
Host: David L. Eisenberg, MD, MPH, FACOG
Guest: David J. Portman, MD
A new form of contraception based on vaginal pH modulation is available. In this activity, Dr. Eisenberg reviews the risks and benefits of the hormone-free, user-controlled gel, and Dr. Portman provides his perspective on clinical trial results within the context of the “creeping Pearl Index.”
Guest: Christie M. Ballantyne, MD
Host: John J. Russell, MD
According to the Consensus Statement published by the European Atherosclerosis Society, more than 90% (and maybe as high as 99%) of individuals with FH in the US have not been properly diagnosed due to gaps in screening, recognition and classification of FH. If not identified and aggressively treated from an early age, individuals with FH have a 20-fold increased life time risk of heart disease compared to the general population. However, with optimal treatment, an affected individual’s lifetime risk of cardiovascular disease approaches the risk found in the general population. Although the clinical symptoms are not as pronounced in cases of heterozygous FH, both homozygous (HoFH) and heterozygous FH (HeFH) patients still have an elevated risk of developing coronary heart disease at some point in their life. Early diagnosis and treatment for both HoFH and HeFH can significantly reduce the risk of coronary heart disease or delay its onset. Both homozygous and heterozygous FH are serious conditions that require special attention and treatment.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chris H. Cooper
Can new mask technology made with innovative materials better protect us from the coronavirus? Dr. Charles Turck speaks with Chris Cooper, Chief Science Officer and CEO of Airlock389, on improving mask technology after the supply shortage of masks during COVID-19.
Guest: Andy Arwari, MD
With more patients opting for home-based care over long-term, acute, and office-based care, it’s important that we align with our patients on what’s most important to them and how they want to be cared for, especially those who are nearing the end of life.
That’s why VITAS Medical Director, Dr. Andy Arwari, is here to share the purpose of goals-of-care conversations and how an app can aid in determining if an advanced illness patient is eligible for hospice.
Host: Michael Miller, MD, FACC, FAHA, FNLA
Guest: Brian Olshansky, MD, FACCP, FAHA, FHRS, FESC
In 2019, the REDUCE-IT trial studying eicosapentaenoic acid (EPA), a purified form of omega-3 fatty acid, was published and demonstrated a dramatic 25% reduction in major cardiovascular events. In 2020, the STRENGTH trial that used a carboxylic acid formulation of combined EPA and docosahexaenoic acid (DHA), was surprisingly neutral and the study was halted for futility. A recent post hoc analysis of the STRENGTH study failed to show a difference in the primary endpoint in the highest tertile group receiving the EPA/DHA carboxylic acid treatment. Why did these two major omega-3 clinical trials studying patients with elevated triglyceride levels have disparate results? What does this mean for our patients? Join two experts, Drs. Michael Miller and Brian Olshansky, as they assess the different trials and offer their perspective on the clinical and scientific implications of the results.
Host: Linda Bradley, MD
In this activity, Dr. Linda Bradley reviews risk factors for uterine fibroids, the use of TVS,
Host: Nanette F. Santoro, MD
In this activity, Dr. Nanette F. Santoro explains risk factors for vasomotor symptoms, reviews current medical options for this bothersome problem, and describes the mechanism of action of a new class of nonhormonal agents: selective neurokinin-3 receptor antagonists.
Host: Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Guest: James A. Underberg, MD
Guest: Nathan D. Wong, PhD, MPH
This activity is presented by outstanding educators in the field of lipidology and preventive cardiology. Join Drs. Erin D. Michos, James A. Underberg, and Nathan D. Wong for a deep dive into these hot topics: new pathways to manage high risk in ASCVD, differential biological effects of omega-3 fatty acids, and practical considerations to manage ASCVD risk.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Michael LaFauci
Guest: Jeffrey Wahl
Drug diversion is a safety concern that is often overlooked. What do we need to know about its impact, and what kind of devices can help? Dr. Charles Turck discusses drug diversion with Michael Lafauci and Jeffrey Wahl from Midas Healthcare Solutions.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Asher A. Kornbluth, MD
Since the onset of the COVID-19 pandemic, many questions have arisen regarding the care of our patients with IBD. Are they at increased risk of COVID-19? How should we treat a patient with IBD who has active COVID-19? Should they get vaccinated, and if so, when? These are all questions Dr. Peter Buch addresses with Dr. Asher Kornbluth, Clinical Professor of Medicine and Gastroenterology at Mount Sinai School of Medicine in New York, to help us optimize our approach to care amid the COVID-19 pandemic.
Host: Neilanjan Nandi, MD
Guest: Kate Scarlata, MPH, RDN
Many patients tailor their diets to their gastrointestinal disorders, such as IBS, and adopt a low FODMAP regimen. What skills do we need to help screen patients for FODMAP sensitivities and identify foods they should avoid? Dr. Neil Nandi will be discussing these skills with Kate Scarlata, a registered dietitian, and a New York Times best-selling author.
Host: Neilanjan Nandi, MD
Guest: Aline Charabaty, MD
Many of us use social media to stay connected with family and friends. But have you ever considered using social media to communicate with other clinicians and even earn CME credit? Clinical Director of Gastroenterology and Director of the Inflammatory Bowel Disease Center at Sibley Memorial Hospital Dr. Aline Charabaty saw that opportunity and used it to create Monday Night IBD, and now Dr. Charabaty is here to talk about that program and the benefits of social media for clinicians with Dr. Neil Nandi.
Host: Vivian Fonseca, MD, FRCP
Guest: Rishi P. Singh, MD
Diabetic macular edema and diabetic retinopathy are 2 of the most common vision complications associated with diabetes. Moreover, diabetic retinopathy is the leading cause of vision loss among adults. We know that screening works, and we have effective treatments, so why do we continue to see high rates of vision loss? Listen as our experts, Dr. Vivian Fonseca and Dr. Rishi Singh, navigate persisting disparities to determine which populations are most vulnerable, the barriers they face, and the potential for emerging strategies to improve screening and vision outcomes for all patients.
Host: Susan L Samson, MD, PhD, FRCPC, FACE
Guest: Kevin C.J. Yuen, MD
Acromegaly is a rare disorder caused by excess growth hormone production and is associated with increased morbidity and mortality. Delays in the diagnosis and initiation of therapy or the provision of suboptimal therapy often negatively impact the quality of life of these patients. Join us for this expert interview with Dr. Susan Samson and Dr. Kevin Yuen who offer insights to help you overcome the complex medical challenges often faced when managing patients with acromegaly, including strategies to apply the latest guidelines and the 2020 consensus statement into clinical practice.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Paller, PhD
Lucid dreaming is complex and remains a mystery to many neurologists, but emerging research suggests we may be able to communicate with dreamers in REM sleep. Dr. Andrew Wilner is joined by Dr. Ken Paller, Northwestern University's Director of the Cognitive Neuroscience program and the training program in the Neuroscience of Human Cognition, to discuss his recent research on communicating with lucid dreamers.
Host: Jennifer Caudle, DO
Guest: Aryeh Shander, MD, FCCM, FCCP
Bleeding is the most common complication of anticoagulant use. And to better care for patients either experiencing acute bleeding or urgently needing surgery, it's critical that clinicians thoroughly understand how to assess, treat, and reverse anticoagulation. Dr. Jennifer Caudle sits down with Dr. Aryeh Shander to discuss some of the different considerations we should take into account when selecting a warfarin reversal option.
Please read full Prescribing Information for Kcentra®.
KCT-0033-APR21
Guest: Carlos del Rio, MD
Guest: Angela Rasmussen, PhD
With cases of COVID-19 surpassing 51 million worldwide, the rush to develop a vaccine capable of slowing the pandemic and lessening the morbidity and mortality of SARS-CoV-2 is underway. Several COVID-19 vaccines are now being studied in phase 3 trials, and clinicians would benefit from a review of these ongoing efforts, particularly the status of vaccines close to approval. This podcast will provide clinicians a review of up-to-date safety and efficacy information on vaccine candidates in late-stage development, and steps to prioritize patients who would benefit most from vaccination once available.
Host: Matthew R. Weir, MD
Guest: Gates B. Colbert, MD, FASN
Guest: Robert Toto, MD
Hyperkalemia (HK) is a major impediment to optimizing RAASi therapy in various patient populations. Fortunately, newer treatments are now available to mitigate this adverse effect. In this chapterized activity, Drs. Colbert, Toto, and Weir discuss strategies to manage a patient with chronic kidney disease (CKD) and resistant hypertension. Find out who is at risk for HK and explore the use of a potassium binder as both a short- and long-term solution.
Guest: Ramiz Kseri, MD
What do we need to keep in mind when treating adolescent transgender patients? Assistant Professor of Clinical Sciences at Florida State University College of Medicine, Dr. Ramiz Kseri, discusses bills impacting transgender rights, hormone blockers, and how we can provide better care for adolescent transgender patients.
Host: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Guest: Joseph Lim, MD
Guest: Danny Chu, MD
Guest: Jian Q. Zhang, DNP, MS, FNP-BC, NEA-BC, FAAN
Experts in chronic hepatitis B within Asian communities discuss prevention, screening and management options to reduce the number of new cases and the risk of progression to cirrhosis, hepatic failure, and hepatocellular carcinoma. Experts also will consider the integration of Western and Eastern Medicine approaches to treatment and how cultural perceptions and community stigmatization of persons of Asian descent with chronic HBV infection can create barriers to diagnosis and care.
Host: Neilanjan Nandi, MD
Guest: Austin Chiang, MD, MPH
The field of endoscopic bariatric weight loss has developed over the years, but there’s a lot we still don’t know. Dr. Neil Nandi is here today with Dr. Austin Chiang, Director of the Endoscopic Bariatric Program at Thomas Jefferson University Hospital, to provide some insight on advanced endoscopy for bariatric weight loss.
Host: Hector O. Chapa, MD, FACOG
ACOG's Annual Clinical and Scientific Meeting will be held virtually this year, but that doesn't mean the content is any less collaborative and impactful. Listen in to hear what ReachMD's host and practicing OB-GYN, Dr. Hector Chapa, is looking forward to at this year's meeting.
Host: Neilanjan Nandi, MD
Guest: Freddy Caldera, DO
Many IBD patients have received their COVID-19 vaccine, but many others still have reservations due to the abundance of myths and misconceptions surrounding the COVID-19 vaccines. That’s why Dr. Neil Nandi welcomes Dr. Freddy Caldera to discuss these common fears and challenges as well as some of the very best answers to address the concerns of our immunosuppressed IBD patients.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Rajeev Attam, MD
Pancreatic cysts may be detected in up to 50 percent of patients undergoing intraabdominal MR imaging. But not all of them are malignant, so how can we determine which patients need further testing, monitoring, and perhaps even surgery? Joining Dr. Peter Buch to answer that and other questions is gastroenterologist Dr. Rajeev Attam.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Colin T. Swales, MD
Should sobriety and drug abstinence be required for hepatitis C therapy? Dr. Peter Buch dives into this dilemma with Dr. Colin Swales, Assistant Medical Director of Transplant Services at Harvard Hospital, as he walks us through both sides of this controversial issue.
Guest: Robert Gottlieb, MD, PhD, FACC
Guest: Marilyn Bulloch, PharmD, BCPS, FCCM
Guest: Tesha Seabra, MSN, RN
Host: Mimi Secor, DNP, FNP-BC, FAANP
As of February 2022, information originally presented in the original broadcast has been updated. Due to the rise of the omicron variant, two combination therapies no longer carry EUA: bamlanivimab+eteseviman and casirivimab+imdevimab.
Neutralizing monoclonal antibodies (mAbs) first received emergency use authorization (EUA) in November 2020 for treating at-risk patients with COVID-19, and the field has continued to evolve since that time. This presentation provides an update in the latest evidence showing reduced severe illness and hospitalization in patients treated with neutralizing mAbs. This presentation will also answer your questions from multidisciplinary expert perspectives in identifying EUA-appropriate patients and administering outpatient infusion therapies: Robert Gottlieb, MD, PhD; Marilyn Bulloch, PharmD, BCPS, FCCM; and Tesha Seabra, MSN, RN.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam Olsen, MS, PA-C
Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.
Host: Joseph F. Goldberg, MD, MS
Guest: Larry Culpepper, MD, MPH
Guest: Andrew A. Nierenberg, MD
Bipolar depression remains a burden for patients living with bipolar I disorder. Therefore, faculty experts came together on World Bipolar Day in a call to action to the healthcare community to improve the diagnosis and treatment of bipolar I depression. In this 60-minute activity previously aired as a live broadcast, faculty review the diagnosis and treatment of a patient case, discussing the utility of tools in diagnosis and strategies to overcome common clinical challenges. An overview of treatments recommended for bipolar I depression is also provided.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Guest: Johannah Ruddy, MEd
Patients suffering from disorders of the gut-brain interaction are often subjected to stigma. But what can we do to help challenge these stigmas? Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to talk about the impact of stigma in DGBI.
Host: Hector O. Chapa, MD, FACOG
Guest: Cameron Ayala
Hundreds of millions of people worldwide suffer from lymphedema and lymphatic diseases. Joining us to provide a personal perspective on this condition is Cameron Ayala, a former reality TV persona, compression specialist, and lymphedema patient who will be sharing his experience with Dr. Hector Chapa.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Andres Nieto, MD
The COVID-19 pandemic has demonstrated the effectiveness of telemedicine, but will this approach still be utilized after the pandemic ends? Dr. Peter Buch is joined by Dr. Andres Nieto, Assistant Professor at Frank H. Netter MD School of Medicine, to discuss the role of telemedicine and its future
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Scott Gabbard, MD
Dyspepsia affects a large number of Americans. But what exactly is dyspepsia? And how can we distinguish dyspepsia from other diseases? Joining Dr. Peter Buch to answer those and other questions is Dr. Scott Gabbard, who’s the section head of the Neurogastroenterology and Motility Center at the Cleveland Clinic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas K. Rex, MD
Millions of colonoscopies are performed each year in the United States, but which indicators should we be using to measure the quality of these procedures? Dr. Peter Buch is joined by Dr. Douglas Rex, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, to discuss the importance of these indicators.
Host: Javed Butler, MD, MBA, MPH
Guest: Paul W. Armstrong, MD
Finding the optimal treatment strategy for patients with worsening heart failure with reduced ejection fraction (HFrEF) can be challenging, and long-term outcomes are poor. Can newer therapies and novel mechanisms of action finally help close the treatment gap for these patients? Join Drs. Javed Butler and Paul Armstrong as they explore these new mechanisms of action and provide practical insights into incorporating newly approved therapies into an overall HFrEF treatment plan.
Host: Shannon L. Meeks, MD
Guest: Jonathan C. Roberts, MD
Dr. Shannon Meeks and Dr. Jonathan Roberts give an overview of the treatments used for the management of hemophilia A and discuss the safety and efficacy of these treatments. Using a patient case, they illustrate the pharmacovigilance process and explain how to implement this important reporting structure into everyday practice.
Host: Shannon L. Meeks, MD
Guest: Cindy Leissinger, MD
Pharmacovigilance begins after clinical trials end and new therapies enter everyday practice. Due to the rarity of hemophilia, participation in clinical trials has necessarily been small, and so monitoring the safety of new hemophilia treatments is especially important. Continued surveillance of adverse drug reactions (ADRs) after approval is a responsibility that falls on all members of the care team.
Dr. Shannon Meeks and Dr. Cindy Leissinger discuss the importance of safety surveillance and monitoring for novel hemophilia A therapeutics. To give a better understanding of pharmacovigilance, this activity includes animation that breaks down the process and illustrates where your ADR reports go and what happens next.
Host: Edward J. Mayeaux, Jr., MD, DABFP, FAAFP
Guest: Paul P. Doghramji, MD, FAAFP
Adherence to CDC vaccination recommendations is a public health issue and a topic of great concern for clinicians. According to the World Health Organization, vaccines ultimately reduce the burden of infectious disease and have the potential to save 2 to 3 million lives a year worldwide independent of their impact on morbidity. Join us as Drs. E.J. Mayeaux and Paul Doghramji discuss the challenges we’re all facing to overcome vaccine hesitancy and improve vaccine uptake, especially during the COVID-19 pandemic.
Host: Neilanjan Nandi, MD
Guest: Sunanda Kane, MD, MSPH, AGAF
Follow Dr. Sunanda Kane and Dr. Neil Nandi as they explore a personalized and proactive treat-to-target strategy to achieve long-term remission in this clinical case scenario of a patient with IBD. Would you make the same decisions?
Host: Neilanjan Nandi, MD
Guest: Russell D. Cohen, MD, FACG, AGAF
New and emerging therapeutic targets will add to the existing portfolio of available biologics and small molecule therapies available in IBD. Join Dr. Russel Cohen and Dr. Neil Nandi as they explore the role of these targets in addressing the various unique IBD phenotypes that lead to loss of response over time, as well as provide practical insights into selecting the right therapy at the right time for your patient.
Host: Neilanjan Nandi, MD
Guest: Folasade P. May, MD, PhD, MPhil
Racial and ethnic bias prevent patients with colorectal cancer from receiving the highest quality of care. Dr. Neil Nandi is joined by Dr. Fola May, Assistant Professor of Medicine at UCLA, to discuss racial inequalities in access to care and screening for patients with colorectal cancer.
Host: Neilanjan Nandi, MD
Guest: Gary R. Lichtenstein, MD, FACG, FACP, AGAF
Achieving remission and long-term success in IBD is greatly dependent on developing a treatment plan that incorporates therapies that induce mucosal healing, reduce inflammation, and that do not possess broad immunosuppressive properties. Join Dr. Gary Lichtenstein and Dr. Neil Nandi as they break down their therapeutic recommendations and patient care approaches. Learn how to develop treatment plans that incorporate early, more aggressive use of targeted therapies and to select the right treatment for the right patient.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Nicole Hanley-Williams, MD
The management of motility disorders like achalasia and gastroparesis can be very complex for both patients and clinicians alike. Fortunately, there have been several advancements in the evaluation and treatment of these disorders. Joining Dr. Peter Buch to walk us through what those developments are and how they can help improve our patients’ quality of life is Dr. Nicole Hanley-Williams, who specializes in motility and functional disorders at Beth Israel Lahey Health.
Host: Neilanjan Nandi, MD
Guest: Miguel Regueiro, MD, AGAF
Treat-to-target is the current standard for the management of IBD, and as such it is imperative to understand what those targets are, what strategies will help you achieve them, and the importance of integrating a patient-focused therapeutic plan. Join Dr. Miguel Regueiro and Dr. Neil Nandi as they explore practical approaches to defining therapeutic success and provide listeners with solutions and recommendations to ultimately improve long-term IBD patient outcomes.
To view and download the Crohn's and Colitis Foundation's appeal letters referenced in this program, click here!
Host: Patricia K. Coyle, MD
Guest: Jiwon Oh, MD
Treatment goals for patients with multiple sclerosis continue to be refined as more and better disease-modifying drugs emerge from clinical trials and we accrue findings from real-world data. Nonetheless, the decision to match a patient with a particular drug agent has become more complex as we strive to achieve our treat-to-target goals and optimize patient outcomes.
Drs. Coyle and Oh discuss how clinicians can best approach the medical management of patients with multiple sclerosis, both in the short and long term. The goal is to apply best clinical evidence while personalizing a patient’s therapy, thus offering the patient as normal a life as possible.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Tyler, MD
Further complicating the COVID-19 pandemic is the emergence of viral variants. Dr. Ken Tyler from the University of Colorado School of Medicine shares with us what we know so far about the COVID-19 variants that are quickly spreading around the world.
Host: Patricia K. Coyle, MD
Guest: Mitzi Joi Williams, MD
While we are witnessing an impressive expansion in the multiple sclerosis treatment landscape, we cannot lose sight of the fact that a critical component of care is the incorporation of best clinical evidence into the personalized management of each patient.
Join us as Drs. Coyle and Williams discuss how bringing shared decision-making into the management of multiple sclerosis can help us to not only achieve our treat-to-target goals, but also improve patient outcomes and satisfaction.
Host: John E. Anderson, MD
Guest: Matthias Hebrok, PhD
Emerging research may offer clinicians an alternative approach to treating type 1 diabetes. Dr. John Anderson meets with Dr. Matthias Hebrok, a professor in diabetes research and director of the Diabetes Center at the University of California, San Francisco, to discuss his groundbreaking research on insulin-producing stem cells.
Host: John E. Anderson, MD
Guest: Matthias Hebrok, PhD
What are the effects of type 1 diabetes on the body? Dr. Matthias Hebrok, a professor in diabetes research and director of the Diabetes Center at the University of California, San Francisco shares some insight on type 1 diabetes and its chronic impact on patients.
Host: Carol Wysham, MD
Guest: Alexis McKee, MD
Patient care has evolved amid the COVID-19 pandemic, causing unexpected challenges in managing diseases such as diabetes. Dr. Carol Wysham joins Dr. Alexis McKee, a practicing endocrinologist and an assistant professor of medicine at Washington School of Medicine in St. Louis, Missouri, to discuss how patients have been overcoming challenges in managing diabetes during the pandemic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Paul Feuerstadt MD, FACG, AGAF
Clostridium difficile impacts many patients around the United States. How can we better diagnose and treat this infection? Dr. Peter Buch is joined by Dr. Paul Feuerstadt, Assistant Clinical Professor of Medicine at Yale New Haven Hospital the discuss the importance of managing Clostridium difficile.
Host: Jacob Sands, MD
Guest: Lawrence Nathan Shulman, MD
How do challenges in our healthcare system and disparities in access to care impact cancer patients within our communities? Dr. Jacob Sands and Dr. Lawrence Shulman continue their important conversation on oncology around the world.
Host: John J. Russell, MD
Guest: Steven W. Pipe, MD
Hemophilia A and hemophilia B are congenital X-linked bleeding disorders caused by deficiency of coagulation factor VIII (FVIII) and IX (FIX). While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies. The preferred treatment option for patients with hemophilia is replacement therapy. Prophylaxis with standard recombinant factor requires regular intravenous infusion at least two (FIX) to three (FVIII) times a week. Recombinant FVIII and FIX products with an extended half-life are currently available and newer strategies are on the horizon. With reported mean half-life extensions of 1.5–1.8 times that of standard products for FVIII and 3–5 times that of standard products for FIX, these therapies have the potential to address and individualize the needs of patients.
Click here to access patient information on hemophilia from the CDC.
Host: Andrew Alexis, MD, MPH
Guest: Linda Stein Gold, MD
Depression, anxiety, failure to thrive, unemployment, low self-esteem, and suicidal ideation. What could possibly be contributing to all of these consequences? The culprit is acne—didn’t expect that, did you? Hear from dermatologists Dr. Andrew Alexis and Dr. Linda Stein Gold as they discuss the proper assessment of acne, its location—particularly beyond the face—and the differences to keep in mind when assessing skin of color. Faculty also examine the role that selective retinoid therapies play in treating acne and preventing the development of both the physical and psychological scars associated with this condition.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Ronnie Fass, MD
Non-cardiac chest pain, NCCP, is chest pain in patients who do not have heart disease. How do we identify and diagnose NCCP? Stay tuned as Dr. Peter Buch talks with Dr. Ronnie Fass, Chief of the Division of Gastroenterology and Hepatology, on the important aspects of non-cardiac chest pain.
Host: Mimi Secor, DNP, FNP-BC, FAANP
Guest: Karen Bloch, MD, MPH, FIDSA, FACP
Guest: Jarrod W. Kile, RPh, BCPS
Hear from a multidisciplinary, interprofessional panel of experts on COVID-19 infusion therapies with virus-neutralizing monoclonal antibodies (mAbs). This activity features a clinical discussion of the Emergency Use Authorization criteria and data from real-world use of mAbs in ambulatory patients. Learn how this treatment reduces the chance of patients with COVID-19 developing severe illness and what could be done to effectively implement the outpatient delivery of mAbs to patients with COVID-19 in your practice.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joshua Stolker, MD
Patients with type 2 diabetes face a higher risk of cardiovascular morbidity and mortality than adults without diabetes. How does this understanding specifically affect the way cardiologists manage their patients with type 2 diabetes? Joining Dr. Charles Turck to explore recently updated recommendations and their impacts on cardiology practice is interventional cardiologist Dr. Joshua Stolker.
To view the 2020 American College of Cardiology Expert Consensus Decision Pathway click here.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20DI00435 February 2021
Guest: Hemal Gada, MD
Guest: Vijay Iyer, MD, PhD, FACC
TAVR-related stroke is a real risk that can seriously impact your patients' quality of life. In this video, Drs. Hemal Gada and Vijay Iyer sit down to discuss the effects of stroke, the role of cerebral embolic protection, and the importance of protecting patients' brains.
Physicians in this episode were compensated for their participation.
Media provided courtesy of Boston Scientific or its affiliates.
Guest: Richard Channick, MD
Guest: Vallerie Mclaughlin, MD
Pulmonary Arterial Hypertension is a progressive disease and is associated with poor clinical outcomes. This first live webinar provides an in-depth discussion of the new thresholds for the diagnosis of PAH, and differential diagnostic considerations, along with the emerging data on the optimal management of patients with PAH. This activity provides a case discussion on the clinical application and effective strategies to integrate the emerging data into treatment regimens to improve outcomes for individuals with this highly complex disease.
Host: Neilanjan Nandi, MD
Guest: Tiffany H. Taft, PsyD
Avoidant Restrictive Food Intake Disorder, AFRID, is a newly introduced eating disorder at the forefront of GI care. Stay tuned to hear Dr. Neil Nandi discuss the impact of ARFID on GI health with Dr. Tiffany Taft, the Director of Psychogastroenterology Research in the Division of Gastroenterology and Hepatology at Northwestern University.
Host: Neilanjan Nandi, MD
Guest: Maria T. Abreu, MD
Environmental factors can affect many different aspects of a patient’s heath, but how do these factors play a role in developing inflammatory bowel disorders, or IBD? Tune in to hear Dr. Neil Nandi and Dr. Maria Abreu, the director of the Crohn’s and Colitis Center at the University of Miami, discuss the role of environmental factors in patients at risk of developing IBD.
Host: John J. Russell, MD
Guest: Adam Hill, MD
Dr. John Russell is joined by pediatric oncologist Dr. Adam Hill, author of “Long Walk Out of the Woods,” to discuss depression among healthcare professionals and address trauma faced in the medical field.
Host: John J. Russell, MD
Guest: Rose George
Dr. John Russell is joined by Rose George, the author of the book “Nine Pints," to take an in-depth look into everything we know about blood.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Joseph C. Anderson, MD
Colon cancer rates for patients younger than 50 have increased at an alarming rate. How can we help screen our younger individuals for colon cancer? Tune in to hear Dr. Peter Buch speak with Dr. Joseph Anderson, Associate Professor of Medicine at Dartmouth, to discuss the transitions occurring in colon cancer screening.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Douglas Drossman, MD
Guest: Johannah Ruddy, MEd
A strong doctor-physician partnership is a critical component of patient care. Here today is Dr. Peter Buch who will be joined by Dr. Douglas Drossman, President of the Rome Foundation, and Ms. Johanna Ruddy, Executive Director of the Rome Foundation, to discuss how to build this foundation and maintain the relationship.
Host: Peter Buch, MD, FACG, AGAF, FACP
While diverticulitis is a common disease, what can be done to help better understand this infection? Here today is our GI Insights host, Dr. Peter Buch, to discuss complications and approaches to managing and treating diverticulitis.
Host: Hector O. Chapa, MD, FACOG
Guest: Robert Owens Carpenter, MD, MPH, FACS, FASMBS
Burnout is a common response to work overload in the field of medicine. What can we do to best avoid this? Dr. Hector Chapa joins Dr. Robert Owens Carpenter, the Texas A&M University College of Medicine’s Director of Wellness, to discuss the importance of managing mental health during the COVID-19 pandemic, not only for patients but healthcare professionals as well.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Devika Umashanker, MD
Obesity is a worldwide phenomenon and linked to morbidity and mortality. How can we help our obese patients along their weight loss journey to ensure long-term success? Dr. Peter Buch is joined by Dr. Devika Umashanker, Obesity Medicine Director of the Department of Bariatric Surgery at Hartford HealthCare Medical Group, to assess strategies for helping your patients see positive long-term weight loss outcomes.
Host: Neilanjan Nandi, MD, FACP
The COVID-19 pandemic has presented a unique set of challenges for healthcare professionals. What are some of the biggest threats to our GI patients, and how should we help them stay safe? Here today is our GI Insights host, Dr. Neil Nandi, to shed some light on his experiences while caring for patients during the pandemic.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Richard Sterling, MD, MSc, FACP, FACG, AGAF, FAASLD
Non-invasive assessments of liver fibrosis can be subcategorized into many different tests. What do we need to know about these increasingly popular assessments? Dr. Peter Buch is joined by Dr. Richard Sterling, professor of medicine at Virginia Commonwealth University to discuss when it is appropriate to use each of these assessments for patients with liver fibrosis.
Host: Hector O. Chapa, MD, FACOG
Guest: Dave McIntosh, PhD, MA
Large communities of color and low socioeconomic status communities are often faced with higher mortality rates due to disparities in healthcare. How do these factors impact patient outcomes? Dr. David McIntosh, vice president and chief inclusion and diversity officer at Wake Forest Baptist Medical Center, discusses how social disparities in race and gender affect patients' outcomes.
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Kyle Staller, MD, MPH
Misconceptions around chronic idiopathic constipation can make it challenging to diagnose and treat. What do we need to know to help our patients manage this condition? Dr. Peter Buch is joined by Dr. Kyle Staller, assistant professor of medicine at the Harvard Medical School to discuss these myths and misconceptions about constipation.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Lee P. Shulman, MD, FACMG, FACOG
Cervical cancer is the fourth most common cancer in women worldwide, which makes it essential for us to keep ahead of advances in cervical cancer prevention—advances like a biomarker-based cytology test. Here to discuss this and other recent advancements in cervical cancer screening is Dr. Lee Shulman, the Anna Ross Lapham Professor in Obstetrics and Gynecology in the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University.
Guest: John J. Russell, MD
With so many COVID-19 vaccines in development, new medical ethical questions have been brought to the forefront of the healthcare field. With that in mind, Dr. John Russell takes us through the history of ethics and vaccinations throughout the world.
Published January 4, 2021
Host: Linda Bernstein, Pharm.D.
The U.S. Food and Drug Administration announced its approval of Ebanga (Ansuvimab-zykl) for the treatment of the ebola virus infection in adults and children. To learn more about the second ebolavirus treatment to receive approval, Dr. Linda Bernstein walks us through this new drug.
Published December 29, 2020
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC, FAANP, FAAN, FNAP
Irritable bowel syndrome, or IBS, is a common disorder that can be challenging to treat. What is the best therapeutic approach to treating this condition? Dr. Peter Buch is joined by Wendy Wright, an adult and family nurse practitioner from New Hampshire, to discuss how to test and treat patients with IBS from a primary care perspective.
Host: John J. Russell, MD
Guest: William G. Callahan, DO
The COVID-19 pandemic has compelled many to stay home, but for those venturing out, how can we encourage them to stay safe? Dr. Bill Callahan, a family physician at Abington Jefferson Health and outdoorsman, sits down with Dr. John Russell to discuss how to stay safe during this winter pandemic.
Host: Linda Bernstein, Pharm.D.
As a growing number of pharmaceutical companies refuse to provide discounts to 340B hospitals for drugs dispensed at community-based pharmacies, a federal lawsuit is challenging the U.S. Department of Health and Human Services in order to fight for patient communities harmed by this refusal. On this episode of The Drug Report, Dr. Linda Bernstein dives into this lawsuit.
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
Dietary decisions play a critical supporting role in the treatment of patients with type 2 diabetes. What kind of impact do these nutritional interventions have? Dr. Kathleen Stanley, a registered dietitian and certified diabetes educator with the Baptist Health Center joins Dr. John Anderson to discuss the impact of dietary recommendations on patients with type 2 diabetes.
Host: Neilanjan Nandi, MD
Guest: Brennan Spiegel, MD, MSHS
Virtual reality has shown the ability to decrease pain, reduce opioid dependence, and boost mental health. How is this digital therapeutic changing the treatment landscape for gastroenterology? Dr. Neil Nandi is joined by Dr. Brennan Spiegel, Director of the Cedars-Sinai CORE program, on his innovative research about the positive impact of virtual reality in gastroenterology.
Host: Linda Bernstein, Pharm.D.
A sedative commonly used in anesthesia, dexmedetomidine hydrochloride has been the subject of many news reports over the past few months. But most recently, the FDA announced approval for Aurobindo Pharma’s dexmedetomidine hydrochloride in 0.9% sodium chloride injection. In this episode of The Drug Report, Dr. Linda Bernstein reviews recent approvals of dexmedetomidine hydrochloride on initially intubated and mechanically ventilated patients.
Published December 17, 2020
Host: John E. Anderson, MD
Host: John Buse, MD, PhD
Host: Carol Wysham, MD
Adhering to treatment can be challenging for many patients with diabetes. Especially for patients on bolus insulin, how can we encourage them to stick to treatment? Tune in to hear Diabetes Discourse hosts Drs. John Buse, Carol Wysham, and John Anderson discuss a patient case and strategies to overcome it.
Host: Linda Bernstein, Pharm.D.
Asthma remains a significant global health problem, and more than 25 million Americans suffer from it. How have the National Asthma Education and Prevention Program’s guidelines changed to help manage this chronic condition? In this episode of The Drug Report, Dr. Linda Bernstein reviews new guidelines on the management of asthma in adolescents and adults.
Published December 10, 2020
Host: Linda Bernstein, Pharm.D.
To prevent the flu from spreading concurrently with COVID-19, The U.S. Food and Drug Administration has expanded the approved indication for baloxavir marboxil to include post-exposure prevention of influenza. On this episode of The Drug Report, Dr. Linda Bernstein dives into this oral anti-influenza drug.
Published December 2, 2020
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: John R. Saltzman, MD
Gastrointestinal bleeding, or GI bleeding, is a serious but common condition, and upper GI bleeding requires an individualized approach. How can we better detect and manage this condition? Dr. Peter Buch will be discussing the importance of managing upper GI bleeding with Dr. John Saltzman, Director of Endoscopy at the Brigham and Women’s Hospital.
Host: Jennifer Caudle, DO
Guest: Roger S. McIntyre, MD, FRCPC
Nationally, approximately 43% of family physicians are providing mental health care, and approximately 25% of patients with depression in a primary care setting may actually have bipolar disorder.1-3 A possible cause of misdiagnosis is that depressive episodes are commonly the initial presentation of the disease.4 Faster recognition and more accurate management of patients with bipolar depression is absolutely critical, explains Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, in an article entitled, Bipolar Depression: The Clinical Characteristics and Unmet Needs of a Complex Disorder.
The open access article is available online at the journal’s website:
Roger S. McIntyre & Joseph R. Calabrese (2019) Bipolar depression: the clinical characteristics and unmet needs of a complex disorder, Current Medical Research and Opinion, 35:11, 1993-2005, DOI: 10.1080/03007995.2019.1636017
References
1. Hirschfeld RMA, Cass AR, Holt DCL, et al. J Am Board Fam Pract. 2005;18(4):233-239.
2. Olfson M, Das AK, Gameroff MJ, et al. Am J Psychiatry. 2005;162:2146-2151.
3. Xierali IM, Tong ST, Petterson SM, et al. J Am Board Fam Pract. 2013;26(2):114-115.
4. Mitchell PB, Goodwin GM, Johnson GF, et al. Bipolar Disord. 2008;10:144-152.
Guest: Pablo F. Mora, MD
The glycemic control algorithm that’s part of the American College of Endocrinology Consensus Statement for 2020 is separated into several parts, and here to break them down for us is Dr. Pablo Mora, Clinical Professor with the Division of Endocrinology at the University of Texas Western Medical Center of Dallas.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00336 October 2020
Host: Jennifer Caudle, DO
Guest: Lisa A. Coco, CRNP
Guest: Deborah Hinnen, APN, BC-ADM, CDCES, FAAN
Guest: Davida F. Kruger, CNP
When a patient with diabetes has cardiovascular disease, they’re at greater risk for morbidity and mortality. That’s why the American Diabetes Association’s 2020 Standards of Medical Care in Diabetes aim to address this and other health risks, and here to walk us through this new treatment algorithm are nurse practitioners Lisa Coco, Debbie Hinnen, and Davida Kruger.
Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2020 Novo Nordisk All rights reserved. US20DI00343 October 2020
Host: Richard K. Bogan, MD
While positive airway pressure is the standard of care treatment for obstructive sleep apnea (OSA), it may not always be enough to address the excessive daytime sleepiness (EDS) that some patients experience. In fact, in one study, up to 34 percent of patients with OSA still reported EDS (Epworth Sleepiness Score ≥10) despite more than 5 hours of CPAP use a night.
Here, Dr. Richard K. Bogan, Associate Clinical Professor at the University of South Carolina School of Medicine and Chairman and Chief Medical Officer at SleepMed, Inc., sheds light on the prevalence of EDS in OSA. Specifically, Dr. Bogan discusses key data that has raised important observations about how commonly EDS may persist even when patients adhere to CPAP therapy.
This promotional, non-CME program is intended for U.S. physicians treating OSA.
Dr. Bogan is a paid consultant of Jazz Pharmaceuticals, Inc.
© 2020 Jazz Pharmaceuticals Inc., a subsidiary of Jazz Pharmaceuticals plc, all rights reserved.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
Infants have the highest incidence of atopic dermatitis in the US but the fewest treatment options. This is a case a doctor submitted about a baby who is refractory to multiple oral and topical treatments. A multidisciplinary panel discusses how they would approach the baby's treatment, emerging options for this vulnerable patient population, and if anything can be done now to prevent progression of the atopic march later.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
Tune in as a multidisciplinary panel discusses a clinician's question about the appropriateness of combining two biologics in a very young child with several atopic diseases.
Guest: Peter A. Lio, MD
Guest: Mark Boguniewicz, MD
Guest: Eric Simpson, MD, MCR
Please note: This activity is no longer available for continuing education credit.
A multidisiplinary panel is presented with a highly allergic, extremely refractory patient with atopic dermatitis. Her dermatologist wants to take the next step and start her on a biologic, but she's worried about the patient's occular history and dupilumab's conjunctivitis risk. Find out what the experts have to say about this doctor's dilemma.
Host: Peter A. Lio, MD
Guest: Eric Simpson, MD, MCR
Guest: Mark Boguniewicz, MD
Please note: This activity is no longer available for continuing education credit.
“I begged my doctor for something else – there had to be something else,” Pam.
For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like.
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 45-minute, case-based CME activity features two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. In addition to the analysis of AI cases, key topics will be covered, including:
- Evaluation for suspected RA
- Combination serological assessment
- 14-3-3eta as a marker for joint damage
- Autoantibodies in SLE diagnosis and classification
- ANA IFA and subserologies
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
Guest: Robert A. Baldor, MD
Guest: Chadwick R. Johr, MD
This innovative, 30-minute, online activity features a Video Expert Dialogue with two prominent faculty covering important, timely issues and data related to the detection of autoimmune (AI) disorders. The emphasis is on the unique role primary care providers play in diagnosing and managing AI and maximizing patient care. Topics include:
- Overview of connective tissue diseases and ANA testing
- ANA IFA and ELISA
- New tests
- Subserologies with IFA
- Choosing wisely about ANA testing
- Diagnosis of RA, Sjögren’s, Lupus, and Systemic Sclerosis
- Titer Information
- Negative ANA testing
- When to refer
We’ll be discussing autoantibody testing for autoimmune diseases, or more precisely, connective tissue diseases. Our purpose here is to discuss how autoantibody testing, such as the ANA, may be used in the primary care setting to diagnose these disorders. Using the ANA test combined with a good medical exam and a good history, along with signs and symptoms of connective tissue diseases, will help to achieve greater benefits in diagnosing and treating patients.
Host: Jennifer Caudle, DO
Guest: Thomas C. Wright, Jr., MD
The Cervical Cancer Screening practice environment continues to change for both physicians and patients. Physicians are constantly tasked with evaluating analyses of new data on how best to approach cervical cancer screening for a particular patient demographic; and patients remain confused and unsure if the “new” approaches are better, or even less safe, than the “Pap” that has served as the bedrock for so many years.
This activity previously aired as a ReachMD Live Broadcast, where Dr. Thomas Wright, Jr., addressed these wide-ranging issues in a real-time, question and answer forum.
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT.
Host: Alicia A. Sutton
Guest: Camille M. Fung, MD
Host Alicia Sutton is joined by Dr. Camille Fung to discuss two areas of public health in Utah that were not addressed by the Utah legislature: opioid addiction and overdose in pregnant women and newborn infants with Neonatal Abstinence Syndrome (NAS). Dr. Fung is an assistant professor at the University of Utah, Division of Neonatology.
Tune in to see how Dr. Fung with her colleagues created enduring material to educate healthcare professionals on the unaddressed public health problem of opioid management without any financial resources.
Guest: David S. Friedman, MD, PhD, MPH
Guest: Steven J. Gedde, MD
Guest: W. Daniel Stamer, PhD
THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.
Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.
In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; …
Host: Jennifer Caudle, DO
Guest: Michael Lewiecki, MD, FACP, FACE
With an incidence rate of more than 750,000 per year, vertebral fractures contribute significantly to morbidity and mortality rates in osteoporosis patients, particularly those who have sustained a VCF in the past. In this new segment, we will hear from Dr. Michael Lewiecki, as he examines this debilitating issue. Dr. Lewiecki is the Director of the New Mexico Clinical Research and Osteoporosis Center; and, Clinical Assistant Professor of Medicine at UNM School of Medicine in Albuquerque, New Mexico.